Epidemiology and management of symptomatic benign prostatic hyperplasia by Verhamme, K.M.C. (Katia)


Epidemiology and Management of  
Symptomatic Benign Prostatic Hyperplasia 
K.M.C. Verhamme
The work presented in this thesis was conducted at the Department of Medical Informatics and 
the Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, the Netherlands.
The author gratefully acknowledges all general practitioners participating in the IPCI database.
Printing of this thesis was financially supported by Yamanouchi Europe.
Cover illustration: “Manneken Pis”, Brussels. Photo by Guy Brusselle.
Layout: Optima Grafische Communicatie, Rotterdam (www.ogc.nl)
Printed by Optima Grafische Communicatie, Rotterdam
ISBN: 90-77595-80-5
© 2004 K.M.C. Verhamme
No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any 
forms of means, without permission of the author, or, when appropriate, of the publisher of the 
publications.
Epidemiology and Management of  
Symptomatic Benign Prostatic Hyperplasia
Epidemiologie en beleid van  
symptomatische benigne prostaathyperplasie
Proefschrift
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam
 op gezag van de Rector Magnificus Prof.dr. S.W.J. Lamberts
 en volgens besluit van het College voor Promoties
De openbare verdediging zal plaatsvinden op 
woensdag 10 november 2004 om 15:45
door
Katia Maria Christina Verhamme
Geboren te Kortrijk (België)
Promotiecommissie
Promotoren:
Prof.dr. B.H.Ch. Stricker
Prof.dr. J.L.H.R. Bosch
Overige leden: 
Prof.dr. J. van der Lei
Prof.dr. J.J.M.C.H. de la Rosette 
Prof.dr. C. van Weel
Co-Promotor: 
Dr. M.C.J.M. Sturkenboom
Aan de IPCI patiënten en de IPCI artsen

Contents
Chapter 1 General Introduction 11
Chapter 2 Incidence and prevalence of lower urinary 
tract symptoms suggestive of benign 
prostatic hyperplasia in primary care.
21
Chapter 3 Prostate specific antigen testing as part 
of the diagnostic work-up by general 
practitioners in patients with incident lower 
urinary tract symptoms suggestive of benign 
prostatic hyperplasia.
31
Chapter 4 Treatment strategies, patterns of drug use 
and treatment discontinuation in men 
with LUTS suggestive of benign prostatic 
hyperplasia.
45
Chapter 5 Low incidence of acute urinary retention in 
the general male population.
59
Chapter 6 Non-steroidal anti-inflammatory drugs are 
associated with an increased risk of acute 
urinary retention.
71
Chapter 7 Anti-psychotic drugs and the risk of acute 
urinary retention.
83
Chapter 8 General Discussion. 97
Chapter 9 Summary & Samenvatting. 115
Dankwoord 121
List of abbreviations 125
Curriculum Vitae 127
 

Manuscripts based on the studies presented in this thesis
Chapter 2
Verhamme KMC, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MCJM. Incidence and 
prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 
Primary Care – The Triumph Project. Eur Urol 2002; 42: 323-328.
Chapter 3
Verhamme KMC, Dieleman JP, Bleumink GS, van Wijk MAM, van der Lei J, Bosch JLHR, Stricker 
BHCh, Sturkenboom MCJM.. Prostate specific antigen testing as part of the diagnostic work-up 
by general practitioners in patients with incident lower urinary tract symptoms suggestive of 
benign prostatic hyperplasia – The Triumph Project. (Submitted).
Chapter 4
Verhamme KMC, Dieleman JP, Bleumink GS, Bosch JLHR, Stricker BHCh, Sturkenboom MCJM. 
Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS 
suggestive of benign prostatic hyperplasia : The Triumph Project. Eur Urology 2003; 44: 539-
545.
Chapter 5
Verhamme KMC, Dieleman JP, van Wijk MAM, Bosch JLHR, Stricker BHCh, Sturkenboom MCJM. 
Low Incidence of acute urinary retention in the general male population – The Triumph Project. 
N Engl J Med 2004; 350: 1359-1361.
Chapter 6
Verhamme KMC, Dieleman JP, Van Wijk MAM, van der Lei J, Bosch JLHR, Stricker BHCh, 
Sturkenboom MCJM. Non-steroidal anti-inflammatory drugs are associated with an increased 
risk of acute urinary retention. (Submitted).
Chapter 7
Verhamme KMC, Dieleman JP, Van Wijk MAM, van der Lei J, Bosch JLHR, Stricker BHCh, 
Sturkenboom MCJM. Anti-psychotic drugs and the risk of acute urinary retention. (Submitted).

Chapter 1: General Introduction

General Introduction
13
Introduction
1.1 Anatomy
The prostate is a walnut-sized gland located just below the urinary bladder around the urethra. 
(figure 1) Its primary function is the secretion of the seminal fluid, which functions to nourish 
and to protect the sperm against the acid pH of the vagina. (1)
Figure 1: Anatomy of the urogenital system of men
1.2 Pathology
Benign prostatic hyperplasia (BPH) is the most common non-cancerous form of cell growth in 
men and usually begins with the formation of microscopic nodules in younger men. As BPH 
progresses, overgrowth occurs in the central area of the prostate, called the transition zone, 
which wraps around the urethra. The stromal component of the prostate is comprised by 
smooth muscle and connective tissue, while the epithelial component is primarily glandular. 
The relationship between the stromal and the epithelial component is approximately 2:1 in the 
normal prostate. In patients with BPH, the stromal to epithelial ratio increases to 5:1.(2)
1.3 Physiology of micturition
The act of micturition is a very complex mechanism. The lower urinary tract consists of the 
bladder and the urethra. Most of the time, the bladder serves as a reservoir for urine and 
expands as the bladder fills. There are two sphincters (internal and external urethral sphincter) 
in the urethral wall that prevent urine loss as the bladder fills. During storage, the distension of 
the smooth muscle fibers and the urothelium, evoke afferent activity. Myelinated Aδ sensory 
fibers respond to passive distension. Unmyelinated C sensory fibers have a higher mechanical 
threshold and respond to a variety of neurotransmitters. These neurotransmitters include 
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adenosine triphosphate (ATP), tachykinins, nitric oxide (NO) and prostanoids. (figure 2) These 
neurotransmitters bind to specific receptors and stimulate or inhibit micturition.(3, 4) 
Figure 2: Role of transmitters in the afferent and efferent pathway
With the initiation of normal urination, urethral resistance decreases via relaxation of the 
internal and the external urethral sphincter, and a phasic contraction of the detrusor muscle 
empties the bladder. A variety of afferent and efferent neural pathways, reflexes and central and 
peripheral neurotransmitters are involved in urine storage and bladder emptying. 
There are 3 nerves that provide primary control of the bladder, namely the hypogastric 
(sympathetic nervous system), the pelvic (parasympathetic nervous system) and the pudendal 
nerves (somatic nervous system). These nerves serve as lower motor neurons and are under 
control of upper motor neurons in the brain stem and the cerebellum. 
Bladder contraction in humans is mainly mediated through stimulation of muscarine 
receptors in the detrusor muscle (parasympathetic pathway). The storage phase of micturition 
is mainly mediated through stimulation of ß3 adrenergic receptors (sympathetic pathway), the 
α-receptors of the urethral internal sphincter (sympathetic pathway) and the urethral external 
sphincter (somatic nervous system). (3, 5, 6)
General Introduction
15
1.4 Epidemiology
Many studies have attempted to assess the prevalence of BPH and none has estimated incidence. 
Assessing the occurrence of BPH is difficult due to the lack of a standardized case definition. 
Based on autopsy studies, the prevalence of histologically diagnosed BPH increases from 8% in 
men aged 31 to 40 years, to up to 40-50% in men aged 51 to 60 years, and to more than 80% in 
men older than 80 years. Based on clinical criteria, approximately 4-25% of men, aged 40 years 
and older, suffer from BPH. Although the observed prevalence of clinical BPH varies depending 
on the definition of BPH, all studies confirm that the prevalence of BPH strongly increases with 
age. (7-13)
Age, normal androgenic function and family history are known risk factors for BPH. Other 
potential risk factors include race, ethnicity, geographic location and obesity.(2, 7)
1.5 Symptomatology
Patients with BPH often express urinary symptoms such as urge incontinence, dribbling, slow 
stream and difficult voiding. These symptoms are not specific for BPH alone. Other causes of 
bladder outflow obstruction (e.g. urethral stricture) and primary disorders of the bladder can 
produce identical symptoms. These symptoms are called lower urinary tract symptoms (LUTS). 
The correlation between the severity of LUTS, prostate size and the degree of obstruction is 
weak. Men with large prostates may be symptom-free while those with small or normal sized 
prostates may sometimes have symptoms that are more severe than in men with larger 
prostates. (2, 7, 14)
Symptomatic BPH is usually defined by the concept proposed by Hald in which the LUTS/BPH 
and bladder outflow obstruction are considered together as presented in fig 3. (15)
Figure 3: Hald diagram showing the interaction between lower urinary tract symptoms, benign prostate enlargement and bladder outlet 
obstruction. 
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Lower urinary tract symptoms are generally classified into voiding symptoms (hesitancy, 
poor urinary flow and need to strain, incomplete bladder emptying, terminal or postmicturition 
dribbling) and storage symptoms (frequency, urgency, nocturia and urge incontinence). To 
quantify the severity and the extent of the LUTS, men are generally asked to complete symptom 
questionnaires. The International Prostate Symptoms Score (I-PSS) has been adopted by the 
World Health Organization and is most frequently used. (2, 7, 8) As well as obtaining objective 
evidence of the severity of LUTS, quantification in terms of effect on quality of life and degree 
of discomfort is equally important. 
1.6 Management of patients with LUTS/BPH
The diagnosis of LUTS/BPH is made on the basis of medical history, physical examination 
including a digital rectal examination, urinalysis and uroflow measurements. To exclude 
prostate cancer, prostate specific antigen (PSA), which is a tumour marker for prostate cancer, is 
often tested. (7, 14) As PSA is often mildly elevated in patients with BPH and thus less conclusive (16), 
guidelines of the Dutch College of General Practitioners on the management of patients with 
difficult micturition, only recommend PSA testing in patients younger than 70 years and with 
an inconclusive digital rectal examination. (17)
BPH is a progressive disease and may lead to important medical conditions such as acute 
urinary retention (AUR), chronic urinary retention, recurrent urinary tract infections, bladder 
calculi and bleeding. (7-9)
The primary goals of treatment for BPH are to reduce the symptoms, to improve the urinary 
flow and eventually to prevent progression. Not every patient with LUTS/BPH is treated and 
some patients are followed with the watchful waiting strategy. Watchful waiting involves 
lifestyle changes such as avoiding alcohol, coffee and avoiding the use of certain drugs (e.g. 
diuretics, decongestants). (2, 7, 14)
The choice between watchful waiting and treatment depends on a number of factors such 
as the severity of the symptoms, the prostate size and the urinary flow rates. Generally, watchful 
waiting is recommended in patients with mild symptoms (I-PSS≤7). Patients with moderate (I-
PSS between 8-19) or severe symptoms (I-PSS ≥20) are pharmacologically treated or undergo 
prostate surgery. (18, 19)
The two drug classes primarily used for the treatment of LUTS/BPH are α-blockers and 5α-
reductase inhibitors. (20) α-Blockers bind to α1-adrenoreceptors in the bladder neck and in the 
smooth muscles of the prostate, causing relaxation and thus improving urinary flow. Some of 
these drugs might also provoke apoptosis of the prostate epithelium. (2, 7, 14) α-Blockers do not 
only provoke a relaxation of the smooth muscles in the prostate, urethra and the bladder neck 
but also cause a relaxation of the smooth muscles of the blood vessels. This might interfere 
with blood pressure regulation, causing all kinds of side effects like (orthostatic) hypotension, 
syncope, dizziness and asthenia. (21)
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5α-Reductase inhibitors suppress the formation of dehydrotestosterone from testosterone. 
This causes atrophy of the prostatic glandular epithelial cells, resulting in a 20-30% reduction 
of the prostate volume after approximately 2-6 months. These drugs are mainly prescribed for 
men with large prostates. (2, 7, 14) Common side effects of 5α-reductase inhibitors are impotence, 
loss of libido and ejaculatory dysfunction. (7)
Recently, results from large randomized controlled trials (RCTs) have been published, showing 
that treatment with 5α-reductase inhibitors and especially the combination of 5α-reductase 
inhibitors with an α-blocker was not only beneficial in the relief of urinary symptoms but was 
also able to prevent disease progression (in terms of acute urinary retention, prostate surgery, 
and urinary tract infections). (22, 23)
Plant extracts have been used for many years in Europe. They might improve the urinary 
flow and relieve nocturia but the exact mechanism of action remains unclear and their efficacy 
needs to be further tested in well-designed, randomized controlled trials (RCT).(7, 20)
If patients are surgically treated, invasive or non-invasive procedures are available. The 
most effective procedures, namely the transurethral resection of the prostate (TURP) and the 
open prostatectomy, are also the most invasive ones. They carry the highest risk of significant 
complications, including impotence and incontinence. Transurethral incision of the prostate, 
transurethral needle ablation and thermotherapy procedures are less invasive. (2, 7, 14)
1.7 Aim and outline of this thesis
Data on the incidence, the natural history and the long term treatment of LUTS/BPH are 
scarce, especially in Europe. Information is only available from some large US cohort studies 
and some large RCTs. (22-25) However, data from these RCTs are not necessarily representative 
of real practice as RCTs only study a highly selected group of patients due to stringent in- and 
exclusion criteria. 
The costs related to the treatment of LUTS/BPH are likely to increase over the coming years 
due to the ageing population and the high prevalence of LUTS/BPH, especially in ageing men. 
Accurate health care policies for the rational management of LUTS/BPH can only be designed if 
information on the management of patients with LUTS/BPH in real practice is available. Under 
the initiative of the European Association of Urology, the Triumph Project (TransEuropean 
Research Into the Use of Management Policies for LUTS suggestive of BPH in Primary Healthcare) 
was initiated to study the real life management of patients with LUTS/BPH in various European 
countries. (26) The Triumph Project consists of 2 parts, namely a prospective and a retrospective 
part. In the prospective part, a cohort of approximately 10,000 LUTS/BPH patients from 6 
European countries is followed over one year to study the various treatment options and to 
study the time to disease progression. The retrospective part of the Triumph Project uses data 
from the General Practice Research Database (GPRD) in the UK and the Integrated Primary 
Care Information (IPCI) project in the Netherlands. (27, 28) The aim of the retrospective part of the 
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Triumph Project is to look into the epidemiology, the management and the clinical progression 
of patients with LUTS/BPH. 
This thesis represents the results of the retrospective part of the Triumph project using data 
from the IPCI database plus some studies on risk factors for acute urinary retention in elderly 
males who do not necessarily have LUTS/BPH. In chapter 2, we describe the incidence and the 
prevalence of LUTS/BPH. In chapter 3, we describe the diagnostic work-up of patients presenting 
themselves with LUTS/BPH. Chapter 4 focuses on the treatment of men with LUTS/BPH including 
compliance aspects such as treatment persistence and treatment adherence. In addition, risk 
factors for early treatment discontinuation are studied. Chapter 5 describes the incidence of 
acute urinary retention as a proxy for BPH progression. Chapters 6 and 7 describe the results of 
a case-control study examining non steroidal anti-inflammatory drugs and antipsychotic drugs 
as risk factor for AUR. 
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Abstract
Objective Benign prostatic hyperplasia (BPH) is one of the most common conditions 
associated with ageing in men. BPH often presents as lower urinary tract symptoms (LUTS) due 
to difficulties in voiding and irritability of the bladder. We conducted a retrospective cohort 
study within the Integrated Primary Care Information Database (IPCI), a general practitioners 
database in the Netherlands, to assess the incidence of LUTS suggestive of BPH (LUTS/BPH) in 
the general population.
Materials Our study population comprised all males, 45 years or older who were registered 
for at least 6 months prior to start of follow-up. The study period lasted from 1st January 1995 
until December 31st 2000. Cases of LUTS/BPH were defined as persons with a diagnosis of 
BPH, treatment or surgery for BPH, or urinary symptoms suggestive of BPH that could not be 
explained by other co-morbidity.
Results The study cohort comprised 80,774 males who contributed 141,035 person-years 
of follow-up. We identified 2,181 incident and 5,605 prevalent LUTS/BPH cases. The overall 
incidence rate of LUTS/BPH was 15 per 1000 men-years (95% CI 14.8-16.1). The incidence 
increased linearly (r2=0.99) with age from 3 cases per 1000 men-years at the age of 45-49 years 
(95% CI 2.4-3.6) to a maximum of 38 cases per 1000 men-years at the age of 75-79 years (95% 
CI 34.1-42.9). After the age of 80 years, the incidence rate remained constant. For a symptom-
free man of 46 years, the risk to develop LUTS/BPH over the coming 30 years, if he survives, is 
45%. The overall prevalence of LUTS/BPH was 10.3% (95% CI 10.2-10.5). The prevalence rate was 
lowest among males 45-49 years of age (2.7%) and increased with age until a maximum at the 
age of 80 years (24%).
Conclusions The incidence rate of LUTS/BPH increases linearly with age and reaches its 
maximum at the age of 79 years 
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Introduction
Benign prostatic hyperplasia (BPH) is one of the most common conditions associated with 
ageing in men, and has been noted at autopsy in approximately 40% of men in their 50s and in 
up to 70% in their 60s.(1) BPH is a benign enlargement of the prostate that results in increasing 
pressure on the urethra and subsequent obstruction of the urinary flow. Patients with BPH 
might be free of symptoms but often present themselves with lower urinary tract symptoms 
(LUTS) as a result of difficulties in voiding (e.g. hesitancy, straining, weak stream, dribbling) and 
irritability of the bladder (e.g. urgency, frequency, urge incontinence).(2)
The prevalence of BPH has already been studied in great detail and results vary from a 
relatively low prevalence of 13% to a high prevalence of 43% depending on the method of BPH 
assessment, the country and the age range studied.(1, 3-10) Despite the abundance of information 
on prevalence, incidence rates of BPH are unknown. Only recently, the incidence of symptoms 
suggestive of BPH has been published.(11,19) 
In the Netherlands the General Practitioner (GP) has a central role and he/she acts as a 
gatekeeper to all further secondary care.(14) Ninety percent of all health problems are dealt with 
by the GP. Patients who develop LUTS suggestive of BPH (LUTS/BPH) would therefore first consult 
their GP for medical care. A diagnosis of BPH will be based on an evaluation of the symptoms (e.g. 
via the International Prostate Symptom Score (I-PSS)), a physical examination including a digital 
rectal examination and urine analysis.(12) Additional examinations such as rectal ultrasound 
and serum analysis of prostate specific antigen (PSA) will be done if indicated.(12) As part of 
the Triumph (TransEuropean Research Into the Use of Management Policies for LUTS/BPH in 
Primary Healthcare) project(13) we conducted a retrospective cohort study within a database of 
computerized GP medical records to assess the incidence of LUTS/BPH diagnosed in the Dutch 
general population.
Methods
Setting
The Integrated Primary Care Information (IPCI) database is a longitudinal observational 
database, which contains information from computer-based records of GPs in the Netherlands. 
Within the Netherlands, patients are registered to a single GP and the record for each individual 
patient can be assumed to contain all medical information on that patient.(14) The IPCI database 
is maintained by the Department of Medical Informatics of the Erasmus Medical Center 
Rotterdam.(15) The first practice was enrolled in the IPCI project in 1992 but a large proportion of 
practices started to contribute from 1998 onwards. Now the number of practices contributing 
data has increased to 98 and the database contains information on approximately 500,000 
patients. 
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The computer records contain information on patient demographics, symptoms (free text), 
diagnoses (using the International Classification for Primary Care), referrals, laboratory values, 
measurements (e.g. blood pressure, cholesterol levels), drug prescriptions plus their ICPC-coded 
indications, and hospitalizations.(16) Summaries of the hospital discharge letters or information 
from specialists are entered in a free text format and copies can be provided upon request. 
Information on drug prescription comprises brand name, quantity, strength, indication, 
prescribed daily dose and the Anatomical Therapeutical Chemical classification (ATC) code.(17) 
To maximize completeness of the data, GPs who participate in the IPCI project are not allowed 
to use paper-based records. The system complies with European Union guidelines on the use 
of medical data for medical research and has been proven valid for pharmaco-epidemiological 
research. (18) 
Study population
The study population comprised all males of 45 years and older who had at least 6 months 
of valid history. A valid history meant that the practice had been contributing data to the IPCI 
database for at least 6 months and that the patient had been registered with the GP for at least 
6 months. Follow-up started on January 1st 1995 or the date that 6 months of valid history were 
obtained, whichever was latest. Follow-up lasted until the first diagnosis of LUTS/BPH, death, 
transferring out of the GP practice or December 31st 2000, whichever was earliest.
Case identification and validation
Since cases of LUTS/BPH cannot be identified with a specific ICPC code we used a sensitive 
computerized case identification method that included diagnoses, treatment and non-coded 
symptoms (text) to minimize the number of undetected cases of LUTS/BPH (false negatives). 
The computerized medical records of all potential incident cases were manually reviewed 
by a medical doctor (KV) and categorized as definite cases of LUTS/BPH if they had LUTS 
and a first diagnosis of BPH; if they had LUTS and were treated with an alpha-blocker or a 5-
alpha-reductase inhibitor for the indication of BPH; if they had two or more LUTS suggestive 
of BPH in absence of any other co-morbidity that could explain these urinary symptoms; or if 
they underwent a prostatectomy for BPH during the follow-up period. Possible cases were all 
persons with a single isolated LUTS and absence of other co-morbidity that could explain the 
urinary symptom, or persons treated with an alpha-blocker without a clear indication for that 
use. Patients were classified as non-cases if the identified symptoms were not related to LUTS 
or if they had LUTS that could be ascribed to other urological conditions (e.g. dysuria related to 
meatal stenosis or urethral stricture). Patients diagnosed with prostate cancer and/or requiring 
prostatectomy for other reasons than BPH were excluded from the analysis and thus did not 
contribute person-years to the denominator. Patients who were first diagnosed with BPH and 
at a later stage were diagnosed with prostate cancer remained in the study but as for all cases, 
follow-up ended at the time of the first record of LUTS/BPH. All possible cases were reviewed by 
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a second medical doctor (GB) and classified as either definite or non-cases after consensus with 
the first reviewer (KV) was obtained. For the final set of definite cases we determined the index 
date as the date of first LUTS/BPH. 
Persons with a diagnosis of BPH, or LUTS prior to study entry were classified as prevalent 
LUTS/BPH patients at study entry and did not contribute persontime to the study. We manually 
validated the medical records of the prevalent LUTS patients who only had one symptom 
by using the algorithm specified above. Patients with prevalent multiple LUTS/BPH were not 
further validated. 
Statistical analysis
The incidence of LUTS/BPH was calculated by dividing the number of men with a first entry of 
LUTS/BPH after study entry by the number of men-years accumulated by the study population. 
Incidence estimates were calculated stratified by age (5-year categories) and calendar year 
and 95% confidence estimates were calculated around the estimates based on the Poisson 
distribution.  
The cumulative incidence of LUTS/BPH over 10, 20 and 30 years of time was calculated from 
the age-specific LUTS/BPH incidence rates that were adjusted for the survival probability in 
each age category. Mortality data (1998) from which we calculated the survival probability were 
obtained from the Dutch Central Bureau of Statistics. (Infoservice@cbs.nl)
Prevalence of LUTS/BPH between 1995 and 2000 was calculated by dividing the number of 
patients of a certain age with prevalent LUTS/BPH by the number of men of that age present 
in the study population. Prevalence estimates were calculated by age with 95% confidence 
intervals calculated on the basis of the normal distribution.
Results
The total study cohort comprised 80,774 males of whom, after a sensitive computer case 
identification algorithm search, 8393 potential incident LUTS/BPH patients and 6055 potential 
prevalent LUTS/BPH patients were identified. After manual validation, 2181 persons were 
classified as definite incident LUTS/BPH cases and 5605 as prevalent LUTS/BPH cases. The 
majority of excluded patients were false positives because of the over-inclusive search on 
symptoms as free text. 
The total person time until development of LUTS/BPH, death, transferring out of the practice 
or December 31st 2000 was 141,035 years. The overall incidence rate of LUTS/BPH was 15 per 
1000 men-years (95% CI: 14.8-16.1). The incidence of LUTS/BPH increased with age, from 3 per 
1000 men-years at the age of 45-49 to a maximum of 38 per 1000 men years at the age of 75-79 
years. After 80 years of age the incidence remained more or less constant (figure 1 and table 1). 
The increase in incidence was linear between ages 45 to 79 years (r2 =0.99) with an increase of 
6.15/1000 men-years upon each 5-year increase in age. 
Mean age at operation 46 years
Mean age at ANA testing 48 years
Indications for mastec tomy
Breast cancer 42
DCIS 21
Prophylactic 8
Paget’s disease 2
Total number of breast recon structi on 73
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Figure 2 shows the 10, 20 and 30 year risk to develop LUTS/BPH for men who are still symptom-
free at a certain age. For a symptom-free man of 46 years, the risk to develop LUTS/BPH over the 
coming 10, -20 or 30 years is 5%, 20% or 45 % respectively (figure 2). For a male who arrives at 
the age of 55 without LUTS symptoms, the risk to develop LUTS/BPH over the next 10, 20 or 30 
years if he stays alive is 15, 40 and 70% respectively.
We also investigated potential changes of age-specific incidence rates over time. Overall the 
incidence of LUTS/BPH was constant over calendar time. The prevalence of diagnosed LUTS/
BPH increased with age. The overall prevalence was 10.3% (95%CI: 10.2-10.5). The prevalence of 
diagnosed LUTS/BPH was lowest at the age of 40-45, namely 2.7% and reached a maximum of 
24.0% at the age of 80 (figure 3). 
Table 1: Incidence of LUTS/BPH
Age Number of incident cases Number of men years Incidence per 1000 
men-years
95%CI
45-49 91 30714.0 2.96 2.40-3.62
50-54 217 31389.7 6.91 6.04-7.88
55-59 278 21354.4 13.02 11.55-14.62
60-64 348 17597.5 19.78 17.78-21.94
65-69 338 14087.1 23.99 21.54-26.66
70-74 378 10969.4 34.46 31.12-38.07
75-79 297 7755.5 38.30 34.12-42.84
80-84 137 4254.4 32.20 27.14-37.94
>84 97 2913.6 33.29 27.15-40.43
Total 2181 141035 15.46 14.83-16.12
Figure 1: Age-specific incidence of LUTS/BPH (--- 95% confidence intervals)
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Figure 1: Age-specific incidence of LUTS/BPH (--- 95% confidence intervals) 
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Figure 2: Age-related risk to develop LUTS/BPH over the coming 10, -20 or –30 years
Figure 3: Age-specific prevalence of LUTS/BPH
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a pattern of occurrence and cannot be translated into a conclusion that age would explain 99% 
of BPH cases; identification of causes of BPH requires another type of study.
In our study, the incidence rate did not further increase after the age of 80 years. This may 
be explained by both underreporting of LUTS by elderly men, by a so-called ‘healthy survivor’ 
effect or by a cohort effect. The healthy survivor effect refers to the natural selection process, 
such that those who reach elder age will tend to be healthier.
From the data on the cumulative incidence we can expect that 45% of the symptom–free 
men aged 46 years will develop LUTS/BPH over the coming 30 years. Since the incidence rate 
increases with age the risk over a fixed period of time increases for men who are older. 
Our prevalence falls within the large range of previously reported prevalence estimates. 
(1,3-10) The large variation in existing prevalence depends on BPH definitions, assessment and 
geographic region. In 1995, a study was published that aimed to show the differences in 
prevalence of BPH with different case assessment methods. (6) The prevalence decreased 
from a high result of 19.3% to a low result of 4% when stricter criteria for case assessment 
(i.e. combination of prostate volume>30 cm, IPSS>7, max flow rate<10mL/sec and presence of 
post-voidal volume > 50mL) were used. A multinational study with case assessment based on 
a standardized symptom questionnaire (I-PSS>7) within a community-based random sampling 
of subjects with age between 40-79 years, showed prevalences of 14%, 18%, 38% and 56% in 
France, Scotland, USA and Japan, respectively. (10) In our study, we found an overall prevalence 
of 10.3%, which is slightly lower than the BPH symptom prevalence of France and Scotland. 
The differences in prevalence between countries could be explained by true differences in the 
occurrence of BPH but might also be the result of cross-cultural differences in the perception of 
the symptoms and the willingness to report them.
Some caution needs to be applied when interpreting our data. First, they should be regarded 
as an approximation of the true prevalence and incidence of BPH in the general population as 
we studied the occurrence of reported symptoms suggestive of BPH. It is likely that we have 
underestimated the actual incidence of BPH due to underreporting and due to asymptomatic 
BPH. (1) Although we applied a rigorous validation algorithm we may have retained some false 
positive persons since we did not always have information on objective criteria such as results 
of rectal ultrasound or uroflowmetry. Also, since there is no international agreement on the 
definition of BPH, some over-reporting of BPH by the GP’s might have occurred. 
In conclusion the incidence rate of LUTS/BPH increases linearly with age and reaches its 
maximum at the age of 79 years. Due to the retrospective character of this study the incidence 
and prevalence estimates should be seen as conservative, but their size and age-related trend 
show the important role that BPH will play as one of the major morbidities in men in an ageing 
population.
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Abstract
Objective: Guidelines of the Dutch College of general practitioners (DCGP) on voiding difficulties 
in older men restrict the use of prostate specific antigen (PSA) in the differential diagnosis of 
lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
Methods: We conducted a retrospective cohort study within the Integrated Primary Care 
Information (IPCI) database to study the use of PSA and digital rectal examination (DRE) as part 
of LUTS/BPH diagnostic work-up. The source population comprised all males, 45 years or older 
during the study period (1st January 1995 to 31st December 2000). From this source population, 
we identified a cohort of men, newly diagnosed with LUTS/BPH and reviewed their medical 
charts for PSA testing and/or digital rectal examination (DRE) around the time of the diagnosis. 
In addition we assessed PSA retesting, referrals to an urologist and eventually prostate biopsy 
within 6 months after initial diagnosis. 
Results: A cohort of 1917 men was diagnosed by the GP as having LUTS/BPH and PSA testing 
was done in 55% of these patients. Of the 277 patients with an abnormal PSA and at least 6 
months of follow-up, 131 (47%) were immediately referred to an urologist, 65 (23%) had a PSA 
retesting and in 81 (29%) no action was taken. Information on DRE was recorded in 1214 of 
the 1917 patients (63%). Among the referred patients, the prostate cancer detection rate was 
highest in patients referred for an abnormal DRE in combination with an elevated PSA (HRadj 
9.8; 95% CI 4.5-21). 
Conclusion: PSA testing occurred in more than 50% of new LUTS/BPH patients but in contrast, 
information on DRE was only recorded in approximately 60% of all patients. Revision of DCGP 
guidelines is desirable to clarify the need, interpretation and follow-up of PSA testing in patients 
with LUTS/BPH.
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Introduction
Prostate-specific antigen (PSA) is used as a tumor marker in the detection and follow-up of 
prostate cancer. PSA testing has become increasingly popular as a screening tool for the early 
detection of prostate cancer. Unfortunately, PSA testing in patients with benign prostatic 
hyperplasia (BPH) provides little additional information about the presence of prostate cancer 
and often leads to false positive results, especially for PSA values between 4-10 ng/ml.(1) While 
widespread use of PSA testing has resulted in the detection of earlier stage prostate cancers, 
many of these tumors were unlikely to be a threat to the overall health of the individual. 
For this reason, the guidelines of the Dutch College of general practitioners (DCGP) on difficult 
micturition in elderly men, recommend PSA testing as diagnostic work-up only in patients 
younger than 70 years with an inconclusive digital rectal examination.(2) Other international 
guidelines are also in disagreement on the role of PSA testing in the initial evaluation of patients 
with LUTS/BPH. (3-6) 
Currently there is no international consensus about the further evaluation of patients with 
an elevated PSA. Three scenarios can be anticipated including: immediate referral for prostate 
biopsy, immediate repeat PSA test or a repeat PSA test after 6-8 weeks. If after repeat testing, PSA 
remains increased, patients should be referred for biopsy. (7) Guidelines of the DCGP recommend 
referral to the urologist for patients suspected to have prostate cancer where therapeutic 
interventions would improve life expectancy or quality of life. This is generally translated into 
referral of patients, younger than 70 years and without severe co-morbidity, who had a digital 
rectal examination (DRE) that was suspicious for prostate cancer or who had an elevated PSA 
test. (2)
Despite the questionable place of PSA testing in improving prostate cancer survival and 
morbidity, this test appears frequently used. In order to get more insight into the diagnostic 
work-up in patients with new LUTS/BPH, we quantified the use of DRE and PSA testing. In 
addition, we assessed the patient management after an abnormal PSA result and estimated the 
risk of prostate cancer among different types of work-up.
Methods
Setting
This study was conducted in the Integrated Primary Care Information (IPCI) database in 
the Netherlands. The IPCI database is a general practice research database, containing 
information from electronic patient records of 150 general practitioners (GPs) covering a total 
of approximately 500,000 patients. In the Dutch health care system, patients are registered 
with a single GP who acts as a gatekeeper of medical care and information.(8) The electronic 
records contain coded and anonymous data on patient demographics, symptoms (using the 
International Classification for Primary Care (ICPC) and free text), diagnoses (using ICPC and 
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free text), clinical findings, referrals, laboratory findings (such as PSA), and hospitalisations.(9, 10) 
Summaries of the hospital discharge letters or information from specialists are entered in a free 
text format and hard copies can be provided upon request. Information on drug prescription 
comprises brand name, quantity, strength, indication, prescribed daily dose, the Anatomical 
Therapeutic Chemical classification (ATC) code and the physician linked indication.(11) To 
maximize completeness of the data, GPs who participate in the IPCI project are not allowed to 
use paper-based records. The system complies with European Union guidelines on the use of 
medical data for medical research and has been proven valid for pharmaco-epidemiological 
research.(12) The Scientific and Ethical Advisory Group of the IPCI project approved the study.
Source population
The study cohort comprised all males of 45 years or older who were newly diagnosed with 
LUTS/BPH by the GP, during the study period (1st January 1995 until 31st December 2000). Details 
on identification and validation of these patients have been published elsewhere. (13) In brief, 
LUTS/BPH was identified from the medical records by manual chart validation. In addition, we 
included all men who presented with LUTS/BPH but who were diagnosed with prostate cancer 
shortly after their first consultation (within 30 days). All cohort members were followed from 
the date of first diagnosis of LUTS/BPH until the end of the study, leaving the practice, diagnosis 
of prostate cancer or death, whichever event occurred first. 
Diagnostic work-up for LUTS/BPH
Use of diagnostic tools, i.e. DRE and PSA testing around the date of diagnosis of LUTS/BPH was 
reviewed in the computerized free text medical records for all study subjects. Total PSA values 
above 4 ng/ml were considered as being abnormal.(14) In addition, we assessed further work-up 
such as repeat PSA testing, referrals to an urologist, or prostate biopsy within the period of 6 
months after a first abnormal PSA result. Only patients with at least 6 months of follow-up after 
initial PSA sampling were included in this analysis. 
According to the DCGP guidelines, the DRE findings as recorded in the patient’s files were 
categorized into 5 categories namely, 1: normal DRE, 2: enlarged DRE, 3: DRE suggestive of 
prostatitis, 4: DRE suggestive of prostate cancer, 5: DRE difficult to interpret.(2) 
Prostate cancer
The occurrence of prostate cancer was assessed during the entire follow-up period after 
diagnosis of LUTS/BPH. Prostate cancer was identified from the electronic medical records 
by automated free text search and search on ICPC code (Y77=prostate cancer) followed by 
validation via manual review. We only included prostate cancers that were either diagnosed or 
confirmed by the urologist. In case of insufficient information, additional information such as 
specialist letters was requested from the GP.
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Analysis
Descriptive statistics were used to describe the frequency of PSA testing, DRE examination, 
urologist referral and prostate biopsies in men with LUTS/BPH. Student’s t-test was used to 
study the difference in means of continuous variables. Chi-square statistics were used for the 
comparison of discrete variables.
Cox proportional hazard analysis was used to study the hazard ratio of prostate cancer in 
patients referred to the urologist based on an abnormal PSA, abnormal DRE or the combination 
of both. To calculate the incidence rate of prostate cancer, we divided the number of cases 
by the total number of person-years, 95% confidence intervals were calculated based on the 
Poisson distribution. The occurrence of prostate cancer was compared between persons with 
different initial work-ups after adjustment for age.
Results
We identified 2214 patients with LUTS/BPH and 22 patients with LUTS who were diagnosed 
with prostate cancer shortly after the LUTS/BPH diagnosis. LUTS/BPH was diagnosed by the 
GP in 1901 of the 2214 patients (86%). A relationship between LUTS, abnormal DRE and the 
probability of prostate cancer was assumed by the GP in 16 of the 22 (72.7%) patients who 
were diagnosed with prostate cancer shortly after their first LUTS-related GP visit. The other 6 
patients were referred to the urologist for LUTS.
Digital rectal examination
Information on DRE of the prostate was recorded in 1214 of the 1917 patients (63 %) diagnosed 
by the GP. The mean age of the patients with a DRE (66 years) was significantly lower than 
the mean age of the patients without (68 years, p<0.001) (table 1). DRE was normal in 366 of 
the 1214 patients (30%). The prostate was enlarged in 738 patients (61%) and suspicious for 
prostate cancer in 73 patients (6%). Nine patients (< 1%) had a DRE that was difficult to interpret 
(table 2). 
PSA testing
Of the 1917 patients diagnosed with LUTS by the GP, PSA testing was performed in 1063 patients 
(55.4%) (figure 1). The mean age of patients with PSA sampling (65 years) was significantly 
lower than in patients without PSA assessment (68 years, p<0.001). PSA testing occurred mainly 
in patients with a DRE (801/1214 (66%) versus 262/703 (37%)) (table 1). The proportion of PSA 
testing was the highest for patients with a DRE, suspicious for prostate cancer (63/73 (86%)) and 
lowest in patients with a DRE, suspicious of prostatitis (10/21 (48%)) (table 2). Even in patients 
with a normal DRE or a DRE suspicious of BPH, the proportion of PSA testing was substantial 
(table 2). 
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PSA turned out to be abnormal in 319 patients (30.0%) with a median PSA level of 7.6 ng/ml. 
Among these patients, 277 had at least 6 months of follow-up after PSA sampling and were 
included in the analysis of further work-up. Among these 277 men, no action, defined as no 
repeat PSA test or no referral to the urologist, was taken in 81 (29%). This group had a median 
PSA level of 5.4 ng/ml. Sixty-six patients (24%) had a repeat PSA testing done and 152 (52%) of 
the patients with an abnormal PSA result were referred to an urologist (figure 1).
Table 1: Use of digital rectal examination and PSA testing in the diagnostic work-up of patients with new LUTS/BPH
DRE
n=1214
No DRE
n=703
Mean age 66 ± 10 * 68 ± 11 P<0.001
PSA testing
- PSA 
- No PSA
801 (66%)
413 (34%)
262 (37%)
441 (63%)
p<0.001
 
* Mean ± SD
Table 2: Use of PSA testing in the diagnostic work-up of patients with new LUTS/BPH, according to DRE result
DRE result
1
n=366
2
n=738
3
n=21
4
n=73
5
n=9
6
n=7
No PSA 139 (38%) 249 (34%) 11 (52%) 10 (14%) 3 (33%) 1 (14%) p< 0,001
PSA 227 (62%) 489 (66%) 10 (48%) 63 (86%) 6 (67%) 6 (86%) p< 0,001
 
1= normal DRE, 2= prostate enlarged, 3= suspect for prostatitis, 4= suspect for prostate cancer, 5= DRE difficult to interpret, 6= DRE result 
lacking
Prostate cancer
Of the 1917 patients diagnosed by the GP as having LUTS/BPH, 1648 patients (86%) had at 
least 6 months of follow-up. Of these patients, 452 (27%) were referred to an urologist within 
6 months after a first diagnosis of LUTS/BPH, 55 (12%) of whom were subsequently diagnosed 
with prostate cancer (Table 3). The prostate cancer hazard ration was highest for patients 
who were referred based on a combination of an elevated PSA and a suspicious digital rectal 
examination (HRadj 9.8; 95% CI 4.5-21) (table 3). 
During the entire follow-up (mean of 1.8 years), we identified 102 cases (5%) of prostate 
cancer amongst the 1917 patients who were diagnosed with LUTS by the GP. This cohort of 
1917 patients with LUTS contributed 3,500 person-years of follow-up resulting in an overall 
incidence rate of prostate cancer of 29.1 per 1000 men-years (95% CI 23.9-35.2). The age 
adjusted incidence rate of prostate cancer amongst the patients with initial PSA sampling was 
higher, though not statistically significant, than the incidence rate of prostate cancer amongst 
the patients without PSA sampling, namely 43.8 per 1000 men-years (95% CI 30.3-57.3) versus 
26.2 per 1000 men-years (95% CI 19.0-35.1) respectively.
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1917 patients diagnosed with LUTS/BPH by GP 
mean age 66
 
Figure 1: Diagnostic work-up in patients with LUTS/BPH 
1917 patients diagnosed with LUTS/BPH by GP 
 
 
No PSA test
N=854 (45%)
Mean age 68 yrs
N= 130
PSA abnormal
N=319
Mean age: 70
Median PSA: 7.6
PSA range: [4.1-8120]
Referral to urologist 
within 6 months
N=152 (55%)
Mean age: 70
Median PSA: 9.95
PSA range: [4.2-8120]
Repeat PSA by GP within 6 months
N=66 (24%)
Mean age: 69
Median PSA: 7.3
PSA range: [4.3-38.5]
Prostate cancer 
diagnosed during 
entire follow-up
N=2
No action taken
N=81(29%)
Mean age: 71
Median PSA: 5.4
PSA range: 4.1-44
At least 6 months follow-up
N=277 (87%)
PSA normal
N=706
Mean age: 63
Median PSA: 1.4
PSA range: [0.02-4.0]
PSA unknown
N=38
PSA test
N=1063 (55%)
Mean age 65 yrs
N=22
Figure 1: Diagnostic work-up in patients with LUTS/BPH
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Discussion
In this study we showed that PSA testing as part of diagnostic work-up took place in 
approximately 50% of all patients diagnosed with LUTS suggestive of BPH. Seventy percent of 
these PSA tests were normal. The majority of patients with an abnormal PSA were referred to 
an urologist, but 30% underwent no follow-up action, in terms of referral or repeat PSA-testing 
at all. DRE was performed in approximately 60% of all patients and mainly in the younger age 
categories. The prostate cancer detection rate was the highest in patients who were referred for 
a combination of abnormal PSA and DRE results.
Although Dutch guidelines on the management of patients with BPH discourage the use of 
PSA sampling, PSA sampling appears to be common practice. (2) Similar results were reported in 
other studies. Two mail surveys reported that 80-90% of primary care physicians reported that 
they routinely use PSA testing. (15, 16) Data from the US Health Professional study showed that 
30-72% of men with LUTS/BPH, aged 47 to 85 years, had a PSA test done in the previous year.(1) 
The high rate of PSA testing in our cohort, could partly be explained by the fact that patients 
with LUTS complaints expect to be tested for the presence of prostate cancer and thus request 
a PSA sampling.(17) In agreement with the Dutch guidelines, PSA mainly occurred in the younger 
age categories suggesting that GPs take the patient’s life expectancy in consideration when 
ordering a PSA test. 
The proportion of patients with a PSA above 4 ng/ml in those who were tested was 30%, 
which is higher than the reported 10-20% in prostate screening programs.(7, 18) This result 
however is not unexpected as we studied a cohort of men with LUTS/BPH and we know that 
PSA is often elevated in patients with BPH. 
Thirty percent of patients with an abnormal PSA result were neither referred to an urologist 
nor were they tested again. From the patient files, it was unclear if GPs deliberately decided not 
to take any action e.g. based on the patient’s life expectancy or if the patient refused further 
diagnostic work-up. It could as well be a consequence of a lack on clear guidelines on the 
management of patients with abnormal PSA results, especially if borderline elevated. 
We found information on DRE only in 63% of all men, despite the fact that DRE is mandatory 
according to the DCGP guidelines. (2) Although recording of the DRE’s might have been omitted 
by the GP, it seems that DRE is not a popular tool in the differential diagnosis for men with 
micturition difficulties. This might be due to the patient’s and physician’s reluctance, inadequate 
skills to interpret the DRE or lack of confidence on the diagnostic value of the DRE. Our results are 
similar to the findings of a recently published US study showing that DRE was only performed 
in 47% of patients screened for prostate cancer.(19) In agreement with the DCGP guidelines, 
mainly patients with DRE recording were tested for PSA. PSA testing however also occurred in 
62-66% of men with a normal DRE or a DRE that was suspicious for BPH. 
Prostate cancer was detected in 12% of all referred patients. The prostate cancer detection 
rate was highest above the age of 65, and in presence of both a DRE suspicious for prostate 
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cancer and an abnormal PSA. This result supports the findings from the Tyrol Screening 
Project that showed that the combination of PSA levels, DRE findings and age influenced the 
probability of a positive biopsy. (20)
The incidence rate of prostate cancer in patients with PSA sampling was higher than the 
incidence rate in patients without PSA testing, though not statistically significant. This suggests 
that PSA sampling is performed based on the probability of having prostate cancer. 
There are limitations to this study and to the interpretation of the findings. First, as this is a 
retrospective cohort study using clinical practice data, we might have missed non-recorded 
data on PSA, DRE, patient referral or prostate biopsy. Since GPs who participate in the IPCI 
project, are not allowed to use paper-based records underreporting will be minimal. Also 
we requested extra information if data on prostate biopsy were missing. A second possible 
weakness is that we did not use age specific PSA reference values.(21) This may have made our 
results more conservative if any. Finally, the incidence rate of prostate cancer should not be 
extrapolated to the general population of males of 45 years and older. The rates were only 
used to study the difference between patients with or without PSA testing. Within the source 
population of 56958 men aged of 45 years and older, 382 cases of prostate cancer were 
identified resulting in a prostate cancer incidence rate of 2.64/1000 men-years (95% CI 2.39-
2.92/1000 men-years). This is slightly lower than reported in the Health Professional Study who 
found a prostate cancer incidence rate of 3.89/1000 men-years.(22)
Recent guidelines suggest to use PSA not only as a marker of prostate cancer, but also as a tool 
to identify those patients with BPH who are likely to progress.(23) PSA sampling is very common 
in this cohort, which underscores the argument that additional PSA sampling to detect BPH 
progression will not increase healthcare costs as it is already routinely done. We also believe 
that the importance of digital rectal examination in the differential diagnosis of patients with 
LUTS/BPH should be re-emphasized, definitely in a GP setting. First of all, DRE is a relative simple 
test and secondly, studies have shown that the positive predictive value of prostate carcinoma 
improves with a combination of an abnormal DRE and an abnormal PSA.(24, 25) 
As long as the results of the European Randomized Study of Screening for prostate cancer 
and the US National Cancer Institute-sponsored Prostate, Lung, Colorectal and Ovarian Cancer 
screening trial on the impact of screening on the prostate cancer mortality are not yet available, 
we agree with the PSA restrictions as outlined in the DCGP guidelines.(26, 27) However; as daily 
practice strongly deviates from what is recommended in these guidelines; a revision of the 
DCGP guidelines is desirable to clarify the need, interpretation and follow-up of PSA testing in 
patients with LUTS/BPH.
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Abstract 
Objectives: We aimed to describe treatment strategies for lower urinary tract symptoms 
suggestive of benign prostatic hyperplasia (LUTS/BPH), adherence to and persistence with 
pharmacological treatment and the association between the type of LUTS/BPH complaints and 
early treatment discontinuation.
Methods: Within a large GP database (IPCI) in the Netherlands we identified all males ≥ 45 years 
newly diagnosed with LUTS/BPH during 1995-2000. Details on treatment were assessed from 
the electronic patient records. Logistic regression analysis was used to estimate the association 
between the type of main urinary complaints and early treatment discontinuation.
Results: Of the 2214 men with incident LUTS/BPH, 1075 received pharmacological treatment 
and 238 underwent prostate surgery. The average adherence differed slightly between drugs: 
67% for α-blockers, 73% for 5α-reductase inhibitors and 71% for combination therapy. 26% of 
the treated patients discontinued treatment early. The probability of early discontinuation was 
higher if patients mainly expressed one type of complaint: voiding- (ORadj 3.38; 95%CI: 1.89-
6.04), post micturition- (ORadj 2.37; 95%CI: 1.15-4.87) or storage symptoms (ORadj 1.85; 95%CI: 
1.16-2.95) as compared to patients expressing a combination of symptoms. The risk of early 
discontinuation was higher if patients had a normal PSA measurement. Older age and a higher 
chronic disease score protected against early treatment discontinuation.
Conclusions: Almost half of newly diagnosed LUTS/BPH patients are pharmacologically treated, 
and a quarter discontinues very rapidly. Stopping early is more frequent among younger 
persons, persons with only one type of main urinary complaint, no other co-morbidity and a 
normal PSA. 
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Introduction
Benign prostatic hyperplasia (BPH) is a common condition in elderly men. Although patients 
with BPH can be without symptoms, they often suffer from difficulties in voiding and/or 
difficulties in storage. The incidence and prevalence of these lower urinary tract symptoms 
suggestive of BPH (LUTS/BPH) increase with age.(1,2)
Treatments of LUTS/BPH comprise watchful waiting, phytotherapy, pharmacological 
treatment and surgery. Watchful waiting is recommended in patients with mild complaints 
without complications, whereas surgery is always considered in those with severe symptoms.(3,4) 
Drug treatment for symptomatic BPH should be considered in patients with moderately 
severe symptoms and moderate obstruction.(5) Pharmacological treatment consists of 5α-
reductase inhibitors (finasteride) and α-blockers (e.g. alfuzosin, doxazosin, prazosin, terazosin 
and tamsulosin). α-Blockers inhibit the α1-adrenergic receptors and have an immediate clinical 
effect by causing a relaxation of the smooth muscle in the prostate, prostate capsule and 
bladder neck, thereby improving urinary flow. (6,7) The 5α-reductase inhibitors on the other hand 
inhibit the formation of dihydrotestosteron, which leads to atrophy of the glandular epithelial 
tissue and consequently to a volume reduction of the prostate. 5α-Reductase inhibitors are 
merely used for patients with large prostatic glands and the time to clinical effect takes two to 
six months.(8) 
Little is known about the treatment and adherence to treatment of LUTS/BPH in general 
practice. We conducted a cohort study in newly diagnosed LUTS/BPH patients to describe the 
treatment strategies, adherence to pharmacological treatment and the association between 
the type of main LUTS/BPH complaints and early treatment discontinuation.(9)
Methods
Setting
This study was conducted in a cohort of patients with newly diagnosed LUTS/BPH who were 
identified from the Integrated Primary Care Information (IPCI) database in the Netherlands. 
The IPCI database is a longitudinal general practitioners (GPs) database, which contains the 
electronic patient records of around 500,000 patients. The electronic patient records contain 
coded and anonymous data on patient demographics, symptoms (in free text), diagnoses 
(using the International Classification for Primary Care and free text), clinical findings, referrals, 
laboratory findings, and hospitalisations.(10-12) Summaries of the hospital discharge letters or 
information from specialists are entered in a free text format and copies can be provided upon 
request. Information on drug prescription comprises brand name, quantity, strength, indication, 
prescribed daily dose and the Anatomical Therapeutic Chemical (ATC) classification code. (13) To 
maximize completeness of the data, GPs who participate in the IPCI project are not allowed to 
use paper-based records. The system complies with European Union guidelines on the use of 
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medical data for medical research and has been proven valid for pharmaco-epidemiological 
research.(14) The Scientific and Ethical Advisory Group of the IPCI project approved the study.
Study cohort
The study cohort comprised all males of 45 years or older with a first diagnosis of LUTS/BPH 
during the study period (01-01-1995 until 31-12-2000). Details on identification and validation 
of these patients have been published elsewhere.(1) 
All cohort members were followed from the date of first diagnosis of LUTS/BPH until the end 
of the study period, leaving the practice, prostate surgery, diagnosis of prostate cancer or death, 
whichever event occurred first. 
Treatment strategies and adherence to therapy
Prostate surgery, pharmacological treatment and phytotherapy were investigated as potential 
treatment strategies. Prostate surgery (both invasive and minimally invasive procedures) was 
identified by automated search from the medical files and subsequent manual review of the 
electronic records. Use of α-blockers (alfuzosin, doxazosin, prazosin, terazosin and tamsulosin), 
and finasteride was identified from the prescription files. Phytotherapy was identified by manual 
review of the medical records. 
We assessed the first type of LUTS/BPH treatment, the time between diagnosis and first 
treatment, duration of, and adherence with treatment. In order to estimate duration of and 
adherence with treatment we created treatment episodes, which accounted for overlap of 
consecutive prescriptions of the same active ingredient. If a patient switched to another drug 
or had a gap (t) between prescriptions of the same drug, a new episode of treatment was 
defined. If two or more different drugs were started on the same day, they were considered 
to be used concomitantly and classified as combination therapy. Adherence to therapy was 
calculated by dividing the duration of an episode (X) by the time that lapsed between the 
start of that treatment episode and the start of a next treatment episode (X+t). (X*100%/(X+t)) 
Treatment-persistence was calculated by dividing the number of days that the patient received 
a pharmacological treatment by the follow-up time since start of first treatment. 
Patients were considered to have discontinued treatment early if they had only one episode 
of pharmacological treatment that lasted less than one-fifth of the follow-up time since start of 
treatment (persistence of less than 20%). The electronic patient records were manually reviewed 
to identify reasons for early discontinuation.
Risk factors for early treatment discontinuation
Variables investigated as potential risk factors for early treatment discontinuation were LUTS 
symptoms, chronic co-morbidity, age, dosing regimen of LUTS/BPH treatment (once daily versus 
multiple dosing), start year of first pharmacological treatment and PSA measurement. 
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LUTS complaints expressed by the patient at diagnosis and at start of drug treatment were 
classified according to the Standardization of Terminology of Lower Urinary Tract Function of 
the International Continence Society.(15) Symptoms were classified as voiding symptoms if the 
patient expressed one or more of the following as main complaints; slow stream, splitting or 
spraying, intermittent stream, need to strain, hesitancy or terminal dribble. Patients were classified 
as primarily having storage symptoms if they had complaints of increased daytime frequency, 
nocturia, urgency or urinary incontinence. Symptoms were classified as post micturition 
symptoms if the patient expressed complaints of a feeling of incomplete emptying and/or post 
micturition dribble. Patients were classified as having a combination of symptoms if they had at 
least one symptom from the storage, the voiding and/or post micturition category. If the reason 
for starting pharmacological treatment was only indicated as BPH or prostatism and no specific 
complaints were listed, the patients were classified as having “prostatism symptoms”.
To measure the general extent of chronic co-morbidities, we calculated the chronic disease 
score (CDS). The CDS is based on the use of drugs as a proxy for long-term diseases, allowing for 
the construction of an overall index of chronic disease status.(16,17)
PSA measurements were identified up until one week after start of LUTS/BPH treatment. 
PSA values were categorized into normal or abnormal based on the reference values of the 
laboratory.
Analysis
The incidence of prostate surgery was calculated by dividing the number of patients with a 
first surgery for LUTS/BPH by the number of person-years accumulated by the cohort of LUTS 
patients. Incidence estimates were calculated by age (5-year categories) and calendar year and 
95% confidence intervals (CI) were calculated based on the Poisson distribution. Kaplan Meier 
survival analysis was conducted to assess the time to prostate surgery and to calculate the one-
year risk of prostate surgery.
Treatment rates were calculated for the newly diagnosed LUTS/BPH patients. Time to first 
treatment was analyzed with Kaplan Meier curves. To describe the type of first treatments 
per calendar year, switching rates, adherence, persistence and early discontinuation the 
denominator included only the treated persons. 
Logistic regression analysis was used to study the association between the type of main LUTS/
BPH symptoms at start of treatment and the risk of early discontinuation of pharmacological 
therapy within the treated population. This analysis was adjusted for all variables that showed 
an association with treatment-discontinuation in the univariate analysis (p<0.05). The patients 
who continued treatment and had a proportion of treated follow-up time of more than 20% 
were used as a reference group.
Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS/BPH
51
Results
The study cohort comprised 2214 men aged 45 years and older who were newly diagnosed 
with LUTS/BPH during the period 1995-2000. Patient characteristics are provided in table 1. 
The average duration of follow-up after diagnosis was approximately 2 years. During follow-up 
238 prostate surgeries were identified leading to an overall incidence of 62.0 per 1000 men-
years (95%CI: 54.4-70.2). In the first year after the diagnosis of LUTS/BPH, the cumulative risk of 
prostate surgery was 8.7% (95%CI: 7.5-10%). The incidence of prostate surgery varied highly by 
age: from 20.7 (95%CI: 4.1-66.3) at the age of 45-49 years to 106.0 per 1000 men-years (95%CI: 
81.5-137.0) at the age of 75-79 years (figure 1). The incidence of prostate surgery decreased over 
time from 141.1/1000 men-years (95%CI: 47.3-336.0) in 1995 to 38.7/1000 men-years (95%CI: 
28.7-51.1) in 2000. 
In total, 1075 patients (48.5%) received pharmacological treatment for LUTS/BPH during the 
study period. Only 16 patients received prescriptions for phytotherapy (saw palmetto extract) 
from their GP. Receiving pharmacological treatment was associated with age (p<0.001), the 
type of urological complaints at diagnosis (p<0.001) and was more likely for persons with more 
co-morbidity (p<0.001) (table 1). 
Table 1: Patient characteristics at time of  LUTS/BPH diagnosis
 
Total number of patients
 (n=2214)
Treated patients
 (n=1075)
Non-treated patients 
(n=1139)
Mean age 66.3 ± 10.4* 67.1 ± 10.2* 65.6 ± 10.5*
Type of LUTS/BPH complaints at 
time of entry in cohort
  Prostatism
  Only storage symptoms
  Only voiding symptoms
  Only post micturition symptoms
  Only voiding and post micturition symptoms
  Combination of storage
 and (voiding and/or post micturition) symptoms
750 (33.9%)
496 (22.4%)
202 (9.1%)
157 (7.1%)
147 (6.6%)
462 (20.9%)
373 (34.7%)
243 (22.6%)
104 (9.7%)
57 (5.3%)
55 (5.1%)
243 (22.6%)
377 (33.1%)
253 (22.2%)
98 (8.6%)
100 (8.8%)
92 (8.1%)
219 (19.2%)
Chronic Morbidity Score (CDS-score)
  CDS 0
  CDS 1-4
  CDS >5
1153 (52.1%)
668 (30.2%)
393 (17.8%)
491 (45.7%)
372 (34.6%)
212 (19.7%)
662 (58.1%)
296 (26.0%)
181 (15.9%)
* mean ±SD
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Figure 1 : Incidence of prostate surgery by age
------- : 95% Confidence Interval
During the first year after diagnosis of LUTS/BPH, 45% of the patients received pharmacological 
treatment, 68% of them received their first prescription within one month after diagnosis.
α-Blockers were the most frequent first line treatment especially in the most recent years 
(figure 2). The median total duration of use of pharmacological treatment was approximately 
3 months (93 days). 645 patients had a follow-up time of more than one year since start of first 
treatment. The mean treatment-persistence (percentage of follow-up time during which drugs 
were used) for these patients was 37% (95%CI; 35-40%). The average adherence to α-blockers 
was 67% (95%CI: 66-68%) which was slightly lower than the adherence rate to 5α-reductase 
inhibitors (73% (95%CI: 69-77%) and the combination therapy (71% (95%CI: 49-93%). The 
adherence rates did not vary substantially within drug classes. 
Figure 2: Proportion of patients treated within one year after diagnosis of LUTS/BPH  according to calendar year
Legend 2: Bars indicate different types of LUTS/BPH treatment used as first treatment. 
Calendar year indicates the year of diagnosis of LUTS/BPH. Only including patients with at least one year follow-up after diagnosis. (n=1591 
(72% of total of 2214 patients)).
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Of the 1075 treated patients, 133 patients (12.4%) switched their first type of drug to another 
compound. The proportion of switchers was statistically higher (p<0.02) for patients first 
treated with alfuzosin (56 out of the 405 patients) than for patients first treated with tamsulosin 
(48 out of the 530 patients). Patients primarily switched because of adverse events, persistence 
of complaints despite treatment or based on the recommendations from the urologist. Of the 
2214 men with LUTS/BPH, 479 (22%) were referred to the urologist. There was no difference in 
referrals between the treated - or the non-treated group. In the former, patients were mainly 
referred after start of the first pharmacological treatment. 
Two hundred and eighty patients out of 1075 (26.0%) discontinued treatment early after 
start. A reason for discontinuation could be identified for almost half (n=130) of these patients. 
The most important reasons were adverse events (n=35), persistence of complaints despite 
treatment (n=31), resolved complaints (n=25) or other reasons (i.e. urologist referral, start 
phytotherapy, n=39). 
The probability of early discontinuation was higher in patients with complaints of mainly 
voiding symptoms (ORadj 3.38 (95%CI: 1.89-6.04)), mainly post-micturition symptoms (ORadj 
2.37 (95%CI: 1.15-4.87)) or mainly storage symptoms (ORadj 1.85 (95%CI: 1.16-2.95) as compared 
to patients complaining of a combination of symptoms (table 2). Patients with a normal PSA 
measurement had a higher risk of early discontinuation (ORadj 1.45; 95%CI: 1.05-2.01) than 
patients without a PSA measurement. Older age (> 60 years) and a higher chronic disease score 
were associated with treatment continuation. A simple once daily dosing regimen as opposed 
to multiple dosing per day was associated with a lower risk of early treatment discontinuation 
but this was not statistically significant when adjusting for all risk factors (ORadj 0.76 (95%CI:0.55-
1.05)).
When repeating the analysis on only these patients who discontinued treatment because of 
adverse events or persistence of complaints (n=66) we found similar point estimates, but only 
the increased risk of early discontinuation in patients mainly complaining of voiding symptoms 
remained statistically significant (ORadj 3.00; 95%CI:1.07-8.43)
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Discussion
This descriptive study on treatment of newly diagnosed LUTS/BPH in the general popula-
tion showed that 8.7% of the population undergoes prostate surgery and that 45% is 
pharmacologically treated within the first year after diagnosis. The most frequent first line 
treatment consists of α-blockers. Treatment is not continuous, the average adherence is 70%, a 
quarter discontinues treatment early and only during a third of the follow-up period, since start 
of therapy, pharmacological treatment is used. The incidence of prostate surgery and the age 
and calendar year pattern is very similar to findings from other studies.(18-24) The percentage of 
treated patients is quite low, which is in accordance with Dutch guidelines that recommend 
watchful waiting for mild complaints, and reserve pharmacological treatment for men with 
moderate to severe symptoms when other measures fail and surgery is contra-indicated. (6)
The main outcomes in evaluating treatment benefits in patients with LUTS/BPH are the 
improvement of subjective symptoms and the impact on the quality of life and on the bother of 
the LUTS/BPH. Long-term adherence and treatment duration are the key to a successful therapy, 
but little has been reported about the actual patterns of use of these drugs in general practice. 
We observed that overall adherence was around 70% with a small variation between α-blockers 
(67%) and 5α-reductase inhibitors (73%). We can not compare our data with information from 
other studies or trials since, to our knowledge; information on adherence to α-blockers or 5α-
reductase inhibitors for treatment of LUTS/BPH has not been published. 
Persistence with therapy was low, 26% of patients discontinued treatment early after start 
mainly because of adverse events, or insufficient treatment efficacy. This is very similar to data 
from two prospective studies that showed that 14-38% of the patients withdrew treatment 
with α-blockers mainly for reasons of adverse effects or lack of efficacy. (25-26) Younger persons, 
persons with only one type of symptom, and patients with less chronic co-morbidity were 
more likely to discontinue treatment early, but this may be confounded by symptom severity. 
It is known that LUTS/BPH worsens with age and that patients with high symptom scores and 
with significant bother will complain less about some minor adverse events of drug therapy 
than a patient with minimal symptoms and bother.(27-28) Especially storage symptoms are very 
bothersome to the patient and have a great impact on the patients’ quality of life.(29-30) Although 
not statistically significant, our results suggest that early discontinuation is lower in patients 
with storage symptoms than in patients who have voiding symptoms. 
Patients with a normal PSA value were more likely to discontinue treatment early than 
patients who had no PSA measurement. Men complaining of LUTS/BPH who turn out to have a 
normal serum PSA value might find reassurance in this result and be less motivated to continue 
treatment. Further studies are needed to test this hypothesis. 
Data from this cohort learns us more about current treatment practice in the general 
population but some caution is needed when interpreting this data. First, since we do not 
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have access to the pharmacy dispensing records or actual intake of drugs, prescription records 
were used to calculate the adherence rate and treatment discontinuation. If patients failed 
to refill their prescription this would mean that we overestimated the average adherence 
and underestimated the treatment discontinuation. Second, the type of symptoms may be 
misclassified or missing because their classification was based on what the GP recorded as 
primary complaints. Details on the type of complaints were lacking for 363 patients as the GP 
only recorded prostatism or BPH. Finally, we do not have systematic and objective information 
on symptom severity since GPs in the Netherlands, according to Dutch guidelines, do not 
routinely ask patients to complete the International Prostate Symptom Severity Score (I-PSS). 
(5,6) 
Conclusion
Almost half of the patients with LUTS/BPH receive pharmacological treatment within one year 
after diagnosis. When patients get treated, the median total duration is only 3 months. Treatment 
is often intermittently used with large gaps between consecutive prescriptions. The chance for 
early discontinuation was highest for patients with mainly voiding symptoms, younger age and 
less co-morbidity. 
As the impact of pharmacological therapy will probably further increase over the coming 
years, patient information and education will be important to increase treatment adherence 
and persistence.
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Abstract
Objective: To describe the incidence of acute urinary retention (AUR) in the general male 
population and in a population of men newly diagnosed with lower urinary tract symptoms 
suggestive of BPH (LUTS/BPH).
Methods: We performed a retrospective cohort study in the Integrated Primary Care 
Information (IPCI) database, a general practice research database in the Netherlands, during 
the period 1995-2000. The study population comprised all males, ≥ 45 years, without a history 
of AUR or radical cystectomy. AUR was defined as the sudden inability to urinate, requiring 
catheterization. Comparison of the AUR-risk between men with and without LUTS/BPH was 
made through Cox-proportional hazard modeling.
Results: Amongst 56.958 males with a mean follow-up of 2.8 years, 344 AUR cases occurred 
(incidence rate 2.2/1000 man-years). Seventy-seven of the 344 cases were precipitated by a 
surgical procedure and 204 had a history of LUTS prior to AUR. AUR was the first symptom of 
LUTS/BPH in 73 (49%) of the 149 AUR cases that occurred in men newly diagnosed with LUTS/
BPH. The risk of developing AUR was 11-fold higher in patients newly diagnosed with LUTS/BPH 
(RR 11.5, 95%CI 8.4-15.6) with an overall incidence rate of 18.3/1000 man-years (95% CI: 14.5-
22.8). 
Conclusions: The incidence of AUR in the general male population is low. The incidence rate 
increases with age and is 11-fold higher in patients newly diagnosed with LUTS/BPH. Since 
49% of AUR cases amongst the LUTS/BPH patients presented with AUR as first symptom, 
earlier patient identification is needed if we aim to reduce the incidence of AUR by means of 
pharmacological treatment. 
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Introduction
Acute urinary retention (AUR) is a condition characterized by a sudden inability to urinate, 
which is usually extremely painful and requires catheterization.(1)
The causes of AUR can be classified into three categories. The first relates to any event that 
increases resistance to the urinary flow such as benign prostatic hyperplasia (BPH).(2) AUR is an 
important complication of BPH and the reason for surgery in 25 to 30% of patients undergoing 
prostatectomy.(3)
Secondly, AUR may result from an interruption of either the sensory innervation of the 
bladder wall or weakness of the detrusor muscle.(2) The third category relates to any situation 
that permits the bladder to over-distend (e.g. post-surgery, drugs).(2) 
The reported cumulative incidence estimates of AUR in males vary widely from 0.4% to 25% 
per year. This variation is related to differences in design, population (e.g. clinical trials versus 
cohort studies) and age distribution and differences in the case definition of AUR.(4-5)
The incidence of AUR in the general male population has been studied in two large 
population–based studies in the US but information in Europe is only available from a small 
cohort study following 456 men over 5 years. (3,6-7) We therefore aimed to assess the incidence 
rate of AUR in a large Dutch male population and to compare it to the incidence rate in patients 
newly diagnosed with lower urinary tract symptoms suggestive of BPH (LUTS/BPH).
Methods
Setting
This study was conducted in the Integrated Primary Care Information (IPCI) database in 
the Netherlands. IPCI is a general practice research database, containing information from 
electronic patient records of 150 GPs covering a total of 500,000 patients. In the Dutch health 
care system, all persons are registered with a single GP, who acts as a gatekeeper of medical 
care and information..(8) The electronic medical records contain coded and anonymous 
data on patient demographics, symptoms (in free text), diagnoses (using the International 
Classification for Primary Care (ICPC) and free text), clinical findings, laboratory findings, 
referrals and hospitalisations.(9) Summaries of the hospital discharge letters or information from 
specialists are entered in a free text format and copies of the letters can be provided upon 
request. Information on drug prescription comprises brand name, quantity, strength, indication, 
prescribed daily dose and the Anatomical Therapeutic Chemical classification (ATC) code.(10) To 
maximize completeness of the data, GPs who participate in the IPCI project are not allowed to 
use paper-based records. The system complies with European Union guidelines on the use of 
medical data for medical research and has been proven valid for pharmaco-epidemiological 
research.(11) The Scientific and Ethical Advisory Group of the IPCI project approved the study.
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Study population 
The study population comprised all males, 45 years or older, with at least 6 months of valid 
database history. A valid history means that the practice had been contributing data to the 
IPCI database for at least 6 months and that the patient was registered with the GP for at least 
6 months. Follow-up started on January 1st 1995 or on the date that 6 months of valid history 
was obtained, whichever was the latest. Patients were excluded when having a history of AUR 
or radical cystectomy, prior to study entry.
To study the incidence of AUR in patients with LUTS/BPH, we identified a sub-cohort of 
patients newly diagnosed with LUTS/BPH during the study period (1995-2000). Details on 
identification and validation of these patients have been published elsewhere. (12) In brief, new 
LUTS/BPH patients were; patients with LUTS and a new diagnosis of BPH, or patients with LUTS 
who were pharmacologically or surgically treated for the indication of BPH, or patients with two 
or more LUTS suggestive of BPH in the absence of any other co-morbidity that could explain 
the urinary symptoms. Patients with a history of BPH or LUTS/BPH prior to the start of follow-
up were considered as prevalent LUTS/BPH patients. Follow-up of the new LUTS/BPH cohort 
started upon diagnosis of LUTS/BPH.
All subjects were followed from study-entry until the first episode of AUR, radical cystectomy, 
the end of the study period, transferring out of the practice or death, whichever event occurred 
first.
Covariates
To measure the general extent of chronic co-morbidities, we calculated the chronic disease 
score (CDS). The CDS is based on the use of drugs as a proxy for long-term diseases and mortality, 
allowing for the construction of an overall index of chronic disease status. (13) In addition, we 
assessed the presence of diabetes mellitus and LUTS/BPH. 
Case identification and validation
AUR was defined as the sudden inability to pass any urine, requiring catheterization. The 
occurrence of AUR was identified from the medical records by searching on ICPC codes U05.2 
(retention), U53 (urinary catheterization) and on free text (“reten”, “cath”, “CAD”). 
All potential cases of AUR were manually reviewed by a physician (KV) and were categorized 
into 3 groups (definite AUR, doubtful AUR and no AUR). An endpoint committee consisting 
of 3 physicians (JLHRB, BS and MVW) reviewed all doubtful cases of AUR. Independently, the 
physicians classified the cases into 3 categories (“AUR”, “no AUR” or “AUR unknown”). If at least 
2 of the 3 physicians agreed, the respective category was assigned. If none of the physicians 
agreed, the AUR case remained doubtful and was not censored in the analysis. 
For all definite AUR cases the patient records were reviewed to check whether the AUR was 
preceded by a procedure (surgery, any urological intervention, and anesthesia), the use of 
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drugs knowing to cause AUR (drugs with anti-cholinergic effect or narcotic analgesics), or by 
an underlying medical condition such as urinary tract infection (UTI), neurological disorders 
and constipation. In addition we checked whether the patients had a history of LUTS consistent 
with the definitions of the International Continence Society14 in at maximum one year prior to 
the AUR.
Analysis
Differences in covariates between patients with or without AUR were tested using Chi-Square 
for categorical data or Student t-test for continuous variables. 
The incidence rate of AUR was calculated by dividing the number of AUR cases by the 
accumulated person-years. Incidence rate estimates were calculated by age (5-year categories) 
and calendar year. 95% confidence intervals (CI) were calculated based on the Poisson 
distribution. Incidence rates were standardized according to the age distribution of the 
Dutch male population using data from the “Central Bureau of Statistics” of the Netherlands. 
(infoservice@cbs.nl)
Cox regression analysis was used to calculate the risk of developing AUR in patients with 
LUTS/BPH (both prevalent and incident), while adjusting for age.
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Results
The total study cohort comprised 56,958 males with a mean age of 58 years. At study-entry, 
4680 patients (8%) had a prior history of LUTS/BPH, the prevalence of diabetes mellitus was 4% 
and more than 70% of subjects had no chronic co-morbidity (table 1). The mean duration of 
follow-up was 2.8 years.
Table 1: Baseline characteristics of the study population
Patients with AUR (%)
n=344
Patients without AUR (%)
n=56614
P value #
Mean age 71.4 ± 10.3* 58.1 ± 11.6* P<0.001
Age categories
 ≥45 - <50 years
≥50 - <55 years
≥55 - <60 years
≥60 - <65 years
≥65 - <70 years
≥70 - <75 years
≥75 - <80 years
≥80 years
9 (2.6)
12 (3.5)
26 (7.6)
32 (9.3)
59 (17.2)
75 (21.8)
49 (14.2)
82 (23.8)
17274 (30.5)
9567 (16.9)
7289 (12.9)
6327 (11.2)
5555 (9.8)
4396 (7.8)
3203 (5.7)
3003 (5.3)
P<0.001
Prevalent LUTS/BPH 84 (24.4) 4596 (8.1) P<0.001
Diabetes mellitus 20 (5.8) 2266 (4.0) P=0.088
CDS categories
CDS 0
CDS 1-4
CDS >4
180 (52.3)
97 (28.2)
67 (19.5)
39844 (70.4)
11509 (20.3)
5261 (9.3)
P<0.001
* mean ±SD
# Chi-square/t-test
After validation, 344 patients were classified as having AUR, 244 (59%) had a history of LUTS 
(storage, voiding or postmicturition symptoms) prior to AUR; 149 of the 344 patients belonged 
to the incident LUTS/BPH cohort. Although the actual cause may be different, 77 AUR cases 
(22%) were preceded by a procedure (surgery, urological interventions, anesthesia) and 72 
(21%) were preceded by an UTI, presence of neurological disorders, or treatment with a drug 
that has been associated with AUR.
The overall incidence of AUR in the general male population was 2.2 per 1000 man-years 
(95% CI: 2.0-2.4). The incidence of AUR increased with age from 0.2 at the age of 45-49 to a 
maximum of 11.0 per 1000 man-years in patients at the age of 80 or older (table 2 and figure 
1). The incidence rate remained stable during the calendar period 1995-1999 and slightly 
decreased in 2000. 
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Table 2: Incidence of AUR within the general male population
Age Number of incident cases Number of men years Incidence rate  per 
1000 man-years
95% CI
45-49 5 31728 0.2 0.1-0.3
50-54 10 32824 0.3 0.2-0.5
55-59 22 23141 0.9 0.6-1.4
60-64 28 19948 1.4 0.9-2.0
65-69 52 16642 3.1 2.4-4.1
70-74 59 13757 4.3 3.3-5.5
75-79 64 10139 6.3 4.9-8.0
≥80 104 9441 11.0 9.0-13.3
Total 344 157620 2.2 2.0-2.4
CI= confidence interval
Figure 1: Age specific incidence rate of AUR in the general male population
The full blue line represent the incidence of AUR for the general male population, 45 years or older. The broken lines represent 95 percent 
confidence intervals.
The overall incidence of AUR within the cohort of 2214 patients newly diagnosed with LUTS/
BPH was 35.9 per 1000 man-years (95% CI: 30.5-42.0) and increased with age (figure 2). Seventy-
three out of the 149 AUR cases (49%) occurring in the cohort, entered this cohort with AUR 
as first symptom of BPH. If we excluded these patients, the overall incidence of AUR was 18.3 
per 1000 man-years (95% CI: 14.5-22.8) (table 3 and figure 2). A similar pattern between age 
and incidence of AUR was found as in the general population (table 3 and figure 2). The risk of 
developing AUR, adjusted for age, was 6-fold higher in patients diagnosed with LUTS/BPH (both 
prevalent and incident) as compared to patients without symptomatic BPH (RR 6.5, 95% CI: 5.0-
8.3). When repeating the analysis, excluding the prevalent BPH patients and the patients with 
AUR as first symptom of BPH, the RR for AUR was 11.5 (95% CI: 8.4-15.6).
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Figure 1: Ag  sp ific incidence rat  f AUR in th  gen ral male population 
The full blue line represent the incidence of AUR for the general male population, 
45 years or older. The broken lines represent 95 percent confidence intervals. 
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Table 3: Incidence of AUR among patients newly diagnosed with LUTS/BPH but without AUR as first presenting symptom
Age Number of incident 
cases
Number of men years Incidence rate per 
1000 man-years
95% CI
45-49 1 98 10.1 0.9-47.3
50-54 0 342 0 0-7.2
55-59 4 502 8.0 2.7-19.0
60-64 7 653 10.7 4.8-21.0
65-69 12 655 18.3 10.0-31.0
70-74 10 780 12.8 6.6-22.8
75-79 18 623 28.9 17.7-44.7
≥ 80 24 498 48.3 31.7-70.6
Total 76 4151 18.3 14.6-22.8
 
CI: confidence interval
Figure 2: Incidence of AUR in the LUTS/BPH cohort
The blue lines represent the incidence with all cases of AUR included. The red line represents the incidence with exclusion of men who presented 
with AUR as the first symptom among lower urinary tract symptoms suggestive of benign prostatic hyperplasia. The broken lines represent 95 
percent confidence intervals.
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Figure 2: Incidence of AUR in the LUTS/BPH cohort 
The blue lines represent the incidence with all cases of AUR included. The red 
line represents the incidence with exclusion of men who presented with AUR as 
the first symptom among lower urinary tract symptoms suggestive of benign 
prostatic hyperplasia. The broken lines represent 95 percent confidence intervals. 
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Discussion
This population-based cohort study showed that AUR is uncommon in a general male population 
of 45 years and older. Within the cohort of men newly diagnosed with LUTS/BPH, AUR is the first 
presenting symptom of BPH in approximately 50% of all AUR cases. The age-adjusted hazard of 
AUR was about 11-fold higher in men with LUTS/BPH than in the general male population. 
Our overall incidence is somewhat lower than the incidence of AUR reported in 2 US cohort 
studies; the Health Professional Follow-up Study (4.5/1000 man-years; 95% CI 3.1-6.2) and the 
Olmsted County (6.8/1000 man-years; 95% CI 5.2-8.9) and a smaller Austrian cohort study 
(3.1/1000 man-years, 7 events per 2270 person years). (3,6-7) This variation in AUR incidence rates 
cannot be explained by differences in age-distribution since our overall incidence rate slightly 
decreased when standardizing for the age distribution of the above-mentioned cohorts. Other 
explanations could be selection bias or differences in AUR diagnosis.
 Selection bias could underlie the higher incidence in the US cohort studies, as one of their 
eligibility criteria was the completion of mailed questionnaires assessing detailed information 
on BPH and urinary symptoms. This is supported by the fact that the prevalence of LUTS/BPH 
and/or diagnosis of BPH was much higher in both the Olmsted County (33% of men had an AUA 
symptom index of more than 8) and the Health Professional Follow-up Study (30% of men had 
clinical diagnosis of BPH) as compared to our general population cohort (8% of men had LUTS/
BPH). In our study, selection bias was excluded as every visit to the physician was prospectively 
monitored in an automated database.
In all 3 cohorts different ways of AUR identification were used. In the Health Professional Study, 
patients were asked by mail if they experienced an episode of AUR requiring catheterization. In 
the Olmsted County, all medical records were reviewed to assess AUR (case definition: urinary 
bladder catheterization for acute retention). The latter definition is in line with ours since we 
also required evidence of catheterization in the medical record.
Using data from the IPCI database gave us the advantage of direct access to prospectively 
gathered and complete access to the medical records of a large population of ageing men. 
Consequently, there was little chance of information or selection bias. In addition, to our 
knowledge, this is the largest cohort study so far studying the incidence of AUR. Because the 
IPCI population is representative of the Dutch population regarding age and gender, we believe 
that our overall AUR incidence rate is a good reflection of the true AUR incidence rate of the 
general Dutch population. 
The overall incidence of AUR in our LUTS/BPH cohort was within the range that was reported 
in other studies (3.7 to 130 per 1000 man-years). (4) This wide range is attributable to various 
factors such as differences in study populations and in case definition. (4-5) Our results are in 
line with recent data from the Proscar® Long-Term Efficacy and Safety Study (Pless) and the 
study from Barry et al. (15-17) The Pless study which compared finasteride to placebo in BPH 
patients reported an AUR-incidence in the placebo treated group of 17/1000 man-years and 
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an AUR-incidence in the finasteride treated group of 7.2/1000 man-years (overall incidence 
12/1000 man-years). Barry et al. followed 371 candidates for elective prostatectomy who were 
treated non-operatively and found an overall incidence of AUR of 25/1000 man-years. The 
MTOPS trial reported an AUR incidence rate of 6/1000 man-years for the placebo group and an 
AUR incidence rate between 1-4/1000 man-years for the active treatment groups (doxazosin, 
finasteride or combination therapy). However, the MTOPS trial excluded all cases of precipitated 
AUR (unless a voiding trial without a catheter was unsuccessful). (18) As more than 40% of AUR 
cases in our cohort were precipitated, this could explain why our AUR incidence rate is higher 
than the one of the MTOPS study.
Recent studies have demonstrated a beneficial effect of medical treatment on the risk of 
AUR. (15-19) In our LUTS/BPH population half of the AUR cases never complained of LUTS/BPH 
prior to AUR which is identical to data from the GPRD. (20) Assuming that medical treatment can 
prevent long term complications of BPH such as AUR, prostate surgery or renal insufficiency, 
earlier LUTS/BPH identification seems to be important. 
Some caution needs to be applied when interpreting this data. Although we used a 
rigorous validation algorithm and strictly followed our case definition, there may be some 
misclassification of the outcome. We might have missed some AUR cases when information on 
urinary catheterization and the details surrounding the AUR (sudden onset, inability to urinate, 
painful or not) were not registered in the patient’s files. However, because AUR is an acute and 
severe event and because GPs in the Netherlands hold the complete medical records of their 
patients, false-negative misclassification is probably modest. 
In conclusion, the incidence rate of AUR in the general population is fairly low, especially in 
the younger age-categories. However, in patients with LUTS/BPH the risk of developing AUR is 
substantial. A large number of men present with AUR as the first symptom of BPH. Therefore, if we 
aim to reduce the incidence of AUR by means of pharmacological treatment, early identification 
of LUTS/BPH patients is essential.
Chapter 5
70
References
 1. Dawson C, Whitfield H. ABC of Urology: Urological emergencies in general practice. BMJ, 312: 838, 
1976
 2. Emberton M, Anson K. Acute urinary retention in men: an age old problem. BMJ, 318: 921, 1999
 3. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors 
for acute urinary retention: The Health Professional Followup Study. J Urol, 162: 376, 1999.
 4. Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Reviews 
in Urology, 3: 187, 2001.
 5. Roehrborn CG. Reporting of acute urinary retention in BPH treatment trials: importance of patient 
follow-up after discontinuation and case definitions. Urology, 59: 811, 2002.
 6. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA et al. Natural history of 
prostatism: Risk factors for acute urinary retention. J Urol, 158: 481, 1997.
 7. Temml C, Brőssner C, Schatzl G, Ponholzer A, Knoepp L, Madersbacher S. The natural history of lower 
urinary tract symptoms over five years. Eur Urol, 43: 374, 2003.
 8. Schrijvers AJP. Health and Health Care in The Netherlands. A critical self-assessment of Dutch experts 
in medical and health sciences. Utrecht: De Tijdstroom; 1997.
 9. van der Lei J, Duisterhout JS, Westerhof HP, van der does E, Cromme WM, Boon WM, et al. The 
introduction of computer-based patient records in the Netherlands. Ann Int Med, 119(10): 1036, 
1993.
 10. Anonymous, ATC and DDD values. Geneva:WHO,1996.
 11. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, van Bemmel 
JH. Postmarketing surveillance based on electronic patient records: The IPCI project. Method Inform 
Med, 38(4/5): 339, 1999.
 12. Verhamme KMC, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MCJM. Incidence and 
prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in Primary 
Care – The Triumph Project. Eur Urol, 42: 323, 2002.
 13. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin 
Epidemiol, 45(2): 197, 1992.
 14. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardization of terminology 
of lower urinary tract function: Report from the standardization sub-committee of the International 
Continence Society. Neurourology and Urodynamics, 21: 167, 2002.
 15. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R et al. Urinary retention in 
patients with BPH treated with finasteride or placebo over 4 years. Eur Urol, 37: 528, 2000.
 16. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride 
on the risk of acute urinary retention and the need for surgical treatment among men with benign 
prostatic hyperplasia. N Engl J Med, 338: 557, 1998.
 17. Barry MJ, Fowler FJ, Bin L, Pitts JC, Harris CJ, Mulley AG. The natural history of patients with benign 
prostatic hyperplasia as diagnosed by North-American urologists. J.Urol, 157: 10, 1997. 
 18. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW et al. The long term 
effects of doxazosin, finasteride and combination therapy on the clinical progression of benign 
prostatic hyperplasial. N Enl J Med, 349: 2387, 2003.
 19. Thorpe A, Neal D. Benign Prostatic Hyperplasia. Lancet, 361: 1359, 2003.
 20. Clifford GM, Logie J, Farmer RDT. How do symptoms indicative of BPH progress in real life practice? 
The UK experience. Eur Urol, 38(suppl 1): 48, 2000.
Chapter 6: Non-steroidal anti-inflammatory drugs are associated with an increased risk 
of acute urinary retention

NSAID's are associated with an increased risk of acute urinary retention
73
Abstract 
Background: Acute urinary retention (AUR) is characterized by the sudden inability to 
urinate, which is usually extremely painful and requires catheterization. Prostaglandins play 
an important role in the genito-urinary function as they provoke contractions of the detrusor 
muscle. Relaxation of the detrusor muscle, via the inhibition of the prostaglandin synthesis, 
could result in AUR. 
Objective: To investigate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) is 
associated with an increased risk of AUR.
Design: Population-based case-control study.
Setting: Data from the Integrated Primary Care Information (IPCI) project in the Netherlands.
Participants: The source population comprised all males, 45 years or older, registered in the 
database between 1995 to 2002 and with at least 6 months of valid history. Cases were all men 
with a validated diagnosis of AUR. Each case was matched on age and calendar time up to 10 
controls.
Main outcome measure: Exposure to NSAIDs in patients with AUR versus exposure to NSAIDs 
in controls, using conditional logistic regression analysis with odds ratios (ORs) and 95% 
confidence intervals (CIs). 
Results: Within the source population of 72 114 men, we identified 536 cases of AUR and 5348 
matched controls. Risk of AUR was 2.26 (95% CI 1.49-3.45) fold higher in current users of NSAIDs 
relative to no use. This increased risk remained when adjusting for all other AUR risk factors 
(ORadj 2.02 (95%CI 1.23-3.31)). The highest risk for AUR (ORadj 3.3, 95% CI 1.2-9.2) was observed 
in patients who recently started using NSAIDs and in those using a high dosage. In studying a 
dose-effect relationship, the increased risk of AUR was present in patients taking 1 defined daily 
dose or more, but absent in the ones taking less than 1 defined daily dose. 
Conclusion: This study shows that the risk of AUR is about 2-fold higher in men who use 
NSAIDs. 
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Introduction
Acute urinary retention (AUR) is a condition characterized by the sudden inability to urinate, 
which is usually painful and requires catheterization.(1) The causes of AUR can be classified 
into three categories. The first category relates to any event that increases the resistance to 
the urinary flow such as benign prostatic hyperplasia (BPH). Secondly, AUR may result from 
an interruption of either the sensory innervation of the bladder or weakness of the detrusor 
muscle. The third category relates to any situation that permits the bladder to over-distend (e.g. 
post surgery).(2) 
Drugs that are known to cause AUR, act via different pathways. Some drugs have direct anti-
cholinergic effects (such as Parkinson medication, antipsychotic drugs) and thus inhibit the 
contraction of the detrusor muscle via the inhibition of the parasympathetic chain. Other drugs, 
such as narcotic analgesics provoke urinary retention via an increased tonus of the external 
sphincter combined with an impaired contraction of the detrusor muscle. The incidence of AUR 
is higher in males than in females, especially in the older age categories, as males suffer more 
often from co-morbidities known to provoke AUR.(3)
In vitro studies have shown that prostaglandins, especially prostaglandin E2, play an 
important role in the genito-urinary function. The prostaglandin synthesis in the bladder 
works via cyclooxygenase-2, and is up-regulated by a number of stimuli such as inflammation, 
trauma, and over-distention.(4) PGE2 stimulates micturition by releasing tachykinins which in 
turn, initiate the micturition reflex by stimulating neurokinin receptors on afferent nerves and 
detrusor smooth muscle. (5, 6) As non-steroidal anti-inflammatory drugs (NSAID) have a direct 
effect on the prostaglandin synthesis, they have been tested in clinical trials for the treatment 
of detrusor instability.(7, 8) Gruenenfelder et al. recently reported 3 cases of AUR that occurred 
within one week upon starting using cyclooxygenase-2 inhibitors.(9) 
The objective of this case-control study in a population of males, 45 years and older, was to 
investigate whether the use of NSAIDs is associated with an increased risk of AUR.
Methods
Setting
This study was conducted in the Integrated Primary Care Information (IPCI) database in 
the Netherlands. The IPCI database is a general practice research database, containing 
information from electronic patient records of 150 general practitioners (GPs) covering a total 
of approximately 500,000 patients. In the Dutch health care system, patients are registered 
with a single GP who acts as a gatekeeper of medical care and information.(10) The electronic 
records contain coded and anonymous data on patient demographics, symptoms (using the 
International Classification for Primary Care (ICPC) and free text), diagnoses (using ICPC and free 
text), clinical findings, referrals, laboratory findings, and hospitalisations.(11, 12) Summaries of the 
NSAID's are associated with an increased risk of acute urinary retention
75
hospital discharge letters or information from specialists are entered in a free text format and 
hard copies can be provided upon request. Information on drug prescription comprises brand 
name, quantity, strength, indication, prescribed daily dose, the Anatomical Therapeutic Chemical 
classification (ATC) code and the physician linked indication.(13) To maximize completeness of 
the data, GPs who participate in the IPCI project are not allowed to use paper-based records. 
The system complies with European Union guidelines on the use of medical data for medical 
research and has been proven valid for pharmaco-epidemiological research.(14) The Scientific 
and Ethical Advisory Group of the IPCI project approved the study.
Source population
The source population comprised all males, 45 years of age or older with at least 6 months of 
valid database history. A valid history meant that the practice had been contributing data to 
the IPCI database for at least 6 months and that the patient had been registered with the GP 
for at least 6 months. This was required to have background information on all subjects. Follow-
up started on January 1st 1995 or the date at which 6 months of valid history was obtained, 
whichever was latest. Patients having a history of AUR or radical cystectomy prior to study 
entry were excluded. All subjects were followed from study-entry until either the first episode 
of AUR, the end of the study period (December 2002), transferring out of the practice or death, 
whichever event occurred first. 
Case identification and validation
AUR was defined as the sudden inability to pass any urine, requiring catheterization. All potential 
cases of AUR were manually reviewed by a physician (KV) and were categorized into 3 groups 
(definite AUR, possible AUR and no AUR). An endpoint committee consisting of 3 physicians 
(JLHRB, BS and MVW) reviewed all cases from the “possible AUR” category. Independently the 
physicians classified the cases into 3 categories (“AUR”, “no AUR” or “AUR unknown”). If at least 
2 of the 3 physicians agreed, the respective category was assigned. If none of the physicians 
agreed, the AUR case remained within the “possible AUR” category. A sample of “possible AUR” 
cases (5%) was verified with the GP and the diagnosis was confirmed in 93% of all cases. 
Review of cases was blinded for exposure to drugs throughout the entire validation process. 
The index date was defined as the date of the first AUR. 
Controls
For each case we sampled up to 10 controls from the source population that was in follow-up 
at the time the case occurred. The controls were matched on age (year of birth) and calendar 
time (index date). 
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Exposure definition
From the prescription records of both cases and controls, all prescriptions for NSAIDs prior to 
the index date were retrieved. The hazard curves for AUR during the use of NSAIDs are not 
known. Based on the proposed mechanism we assumed a priori an acute effect with a short 
carry-over. Hence, exposure to NSAIDs was classified as current (last prescription covers the 
index date or ends less than 2 days prior to the index date) and past (last prescription ended 
more than 2 days and less than 6 months prior to the index date). For current users of NSAIDs, 
the dose effect with daily dose in DDD (< 1 Defined Daily Dose (DDD), 1 DDD, > 1 DDD per day) 
and the treatment-duration effect were studied. The DDD is the recommended average dosage 
of a drug for an adult for the main indication, as defined by the World Health Organization.(13) 
To study the effect of time since first use we categorized current users of NSAIDs into recent 
starters (patients who received their prescription for an NSAID within one week prior to the 
index date while not having used NSAIDs in the past 6 months) and long term users (patients 
currently using NSAIDs for more than one week or patients who had used NSAIDs in the past 
6 months and who received their prescription for an NSAID within one week prior to the index 
date). To investigate the influence of affinity to COX-2, we compared COX-2 selective inhibitors 
with non-selective COX inhibitors. 
In addition, we retrieved all prescriptions for acetylsalicylic acid prior to the index date and we 
examined the effect of current use of acetylsalicylic acid, using the same definitions as stated 
above, either as analgesic or as platelet inhibiting agent.
Covariates
Information on the presence of different risk factors for AUR was extracted from the 
computerized patient records. These concerned current use of concomitant drugs known to 
cause AUR (drugs with anticholinergic effect, narcotic analgesics and benzodiazepines); a recent 
(within 30 days prior to the index date) history of urinary tract infection (UTI), nephrolithiasis, 
constipation, surgery and home bound lifestyle. In addition, we checked for a history of BPH, 
prostate cancer, incontinence, diabetes mellitus, cardiac diseases, cancer, stroke, dementia 
and other neurological disorders prior to the index date. Finally, we checked all indications for 
current use of NSAIDs from the patient’s prescription records.
Statistical analysis
The incidence of AUR within this population was calculated by dividing the number of men 
with AUR by the number of men-years accumulated by the source population. 95% confidence 
estimates were calculated around the estimates based on the Poisson distribution.
Conditional logistic regression analysis was used to assess the matched unadjusted and 
adjusted risk estimates for the association between risk factors and AUR and exposure to 
NSAIDs and the occurrence of AUR. In the adjusted model we first included, one by one, all co-
variates that were univariately associated with the outcome (p<0.05). Risk factors that changed 
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the relative risk of AUR following current use of NSAIDs by more than 5% were maintained in 
the final model. 
To estimate the proportion of AUR in the total population that can be attributed to the current 
use of NSAIDs we calculated the Population Attributable Risk (PAR) using the following formula (15): 
PAR= Attributable risk x proportion exposed
In this formula, the attributable risk is the incidence rate among the exposed minus the 
incidence rate among the unexposed. The proportion exposed is the proportion of current 
NSAIDs users among the controls (assuming to be representative of the general population). 
All statistical analyses were conducted with the statistical software packages SPSS/PC 11.5.
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Results
Within the source population of 72,114 males, 45 years of age or older, we identified 536 definite 
and 25 possible cases of AUR, the incidence was 2.4 per 1000 men-years (95% CI 2.25-2.65 per 
1000 men-years). To avoid false-positive misclassification of the outcome, we only used the 
definite cases in our case-control analyses. These 536 definite AUR cases were matched to 5348 
controls. 
The mean age of cases was 73.0 years (SD 10.4). Cases had a higher prevalence of co-morbidity 
such as BPH, prostate cancer, neurological disorders and cancer and more often had a history of 
urinary tract infections, constipation, surgery and home bound lifestyle than controls (table 1). 
Current use of drugs with anticholinergic effects, narcotic analgesics and benzodiazepines was 
also higher among cases than among controls (table 1).
Table 1: Patient characteristics and the univariate association with AUR
Cases Controls ORmatched* 95% CI
 (n=536) % (n=5348) %
Comorbidity
BPH 228 42.5 966 18.1 3.48 2.88-4.21
Prostate cancer 52 9.7 143 2.7 3.88 2.79-5.40
UTI 45 8.4 14 0.3 39.56 20.44-76.66
Urolithiasis 2 0.4 2 0.0 10.0 1.4-71.0
Urinary incontinence 22 4.1 105 2.0 2.15 1.34-3.46
Surgery 74 13.8 34 0.6 23.89 15.62-36.55
Constipation 22 4.1 23 0.4 9.83 5.44-17.76
Diabetes mellitus# 51 9.5 473 8.8 1.08 0.80-1.46
Cardiac diseases 176 32.8 1491 27.9 1.27 1.05-1.55
Stroke 38 7.1 255 4.8 1.54 1.08-2.20
Dementia 7 1.3 44 0.8 1.6 0.7-3.6
Neurological disorders 12 2.2 61 1.1 1.97 1.05-3.70
Cancer 39 7.3 165 3.1 2.48 1.72-3.56
Home bound lifestyle 159 29.7 476 8.9 5.43 4.30-6.86
Concomitant Medication
Use of anticholinergic drugs 57 10.6 356 6.7 1.80 1.33-2.43
Use of narcotic analgesics 28 5.2 62 1.2 4.61 2.93-7.26
Use of benzodiazepines 49 9.1 310 5.8 1.68 1.22-2.31
 
* matched on year of birth and indexdate  #risk of AUR was increased  in patients with long lasting diabetes mellitus type 1 
(OR matched 4.1 (95% CI 1.3-13.5))
The unadjusted OR for AUR was 2.26 (95% CI 1.49-3.45) for current use of NSAIDs compared 
to no use. This increase in risk remained upon adjustment for other AUR risk factors with an OR 
of 2.02 (95%CI 1.23-3.31) (table 2). Past use of NSAIDs was not associated with an increased risk 
of AUR. Among current users, the risk was highest for persons who were new NSAIDs users (ORadj 
3.3, 95% CI 1.2-9.2) whereas the risk for long-term users was 1.77 (95% CI 1.01-3.10) (table 2). 
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The risk of AUR was not linearly related with dose. No association with current use of low 
doses of NSAIDs (<1 DDD) was observed, and there was a similar increase in risk for patients 
taking NSAIDs at a dose of 1 DDD or higher (table 2). 
Table 2: NSAID use (excluding acetylsalicylic acid) and the risk of AUR
 AUR cases Controls ORmatched* (95% CI) ORadj # (95% CI)
(n=536) % (n=5348) %
NSAID 
No use
Current use
Past use
448 
28 
60 
83.6
5.2
11.2
4715 
131
502
88.2
2.4
9.4
reference
2.26 (1.49-3.45)
1.26 (0.95-1.67)
reference
2.02 (1.23-3.31)
0.98 (0.70-1.37)
Duration of NSAID use
No use
Current use
•  Started less  
than 8 days
•  Started more  
than 8 days
Past use
448
6 
22
60 
83.6
1.1
4.1
11.2
4715 
16 
115 
502 
88.2
0.3
2.2
9.4
reference
3.9 (1.5-9.9)
2.02 (1.27-3.24)
1.26 (0.95-1.67)
reference
3.3 (1.2-9.2)
1.77 (1.01-3.10)
0.98 (0.70-1.37)
NSAID DDD
No use
Current use
• <1 DDD
•    1 DDD
• >1 DDD
Past use
448 
2 
11
15 
60 
83.6
0.4
2.1
2.8
11.2
4715 
41
37
53 
502 
88.2
0.8
0.7
1.0
9.4
reference
0.5 (0.1-2.1)
3.12 (1.59-6.12)
3.06 (1.70-5.50)
1.26 (0.94-1.67)
reference
0.4 (0.1-1.9)
3.33 (1.56-7.11)
2.38 (1.18-4.79)
0.99 (0.70-1.38)
 
* matched on year of birth and index date # adjusted for BPH, prostate cancer, UTI, surgery, home bound lifestyle and use of narcotic analgesics 
and benzodiazepines.
In a further attempt to explore whether any potential effect would be restricted to NSAIDs 
with high affinity for COX-2 we estimated the AUR risk for the COX -2 selective inhibiting NSAIDs 
and the nonselective NSAIDs. Use of COX-2 selective inhibitors was associated with a somewhat 
higher risk of AUR then use of non-selective NSAIDs (table 3). However, there were few users 
of COX-2 selective drugs and the risk estimates for COX-2 selective and non-selective NSAIDs 
were similar after adjustment for the daily dose (rofecoxib is usually prescribed twice the 
recommended daily dose). 
The risk of developing AUR in patients currently using acetylsalicylic acid was not increased 
(OR 1.25, 95% CI 0.98-1.60), however the majority of persons (95%) used it in low doses (< 100 
mg) (table 3). 
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Table 3: Type of NSAID or acetylsalicylic acid and risk of AUR
 AUR cases Controls ORmatched* (95% CI) ORadj # (95% CI) ORadj ¥ (95% CI)
(n=536) % (n=5348) %
Type of NSAID 
No use
Current use of 
-  cox-2 selective  
NSAIDs
-  non cox-2 
selective 
NSAIDs
Past use
448 
3 
25 
60
83.6
0.6
4.7
11.2
4715 
8
123
502 
88.2
0.1
2.3
9.4
Reference
4.4 (1.1-17.9)
2.15 (1.38-3.34)
1.26 (0.95-1.68)
Reference
3.1 (0.5-17.6)
1.96 (1.17-3.26)
0.96 (0.70-1.37)
Reference
1.8 (0.1-25.4)
1.40 (0.38-5.20)
0.98 (0.70-1.38)
Acetylsalicylic acid
Current use
Past use
90
30
16.8
5.6
756
257
14.1
4.8
1.25 (0.98-1.60)
1.22 (0.83-1.81)
0.99 (0.74-1.32)
0.86 (0.54-1.38)
-
-
* matched on year of birth and indexdate # adjusted for BPH, prostate cancer, UTI, surgery, home bound lifestyle and use of narcotic analgesics 
and benzodiazepines. ¥ adjusted for BPH, prostate cancer, UTI, surgery, home bound lifestyle and use of narcotic analgesics, benzodiazepines and 
DDD
The indication for NSAIDs was not substantially different between cases and controls and 
the indication for current use of NSAIDs (both for cases and controls) was locomotoric in more 
than 70%. Amongst the cases, none of the recent starters of NSAIDs had a urological condition 
as indication for treatment start. 
We explored effect modification by age, presence of urinary tract infection, a history of BPH, 
prostate cancer, use of concomitant medication such as anticholinergics or narcotics. We did 
not identify significant effect modification by any of these variables. 
Finally, based on an incidence rate of AUR of 4.73 per 1000 men-years amongst the exposed 
and of 2.34 per 1000 men-years among the unexposed, we calculated a PAR of 57.4/106/year. 
Using demography data from the Dutch Central Bureau of Statistics (infoservice@cbs.nl) and 
based on an overall AUR incidence rate of 2.4 per 1000 men-years in males 45 years and older, 
this would mean that for 1998, 6548 new cases of AUR were expected in males 45 years and 
older of whom 156 (2.4%) could be attributed to the current use of NSAIDs.
Discussion
In this study, we showed that current use of NSAIDs is associated with an increased risk of acute 
urinary retention (AUR). The risk is highest in patients who recently started using NSAIDs and 
those who use high daily dosages. To our knowledge, this is the first epidemiological study 
reporting on the association between the use of NSAIDs and the risk of AUR. The hypothesis 
as postulated by Gruenenfelder et al. was that the inhibition of cyclooxygenase-2 might result 
in AUR.(9) After adjusting for all risk factors and for dose, we did not observe a difference in risk 
between the selective COX-2 inhibitors and the non-selective other NSAIDs. This would seem 
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plausible, since COX-2 will be inhibited by COX-2 specific inhibitors but also by non-selective 
NSAIDs.(5) We did not find an association between current use of acetylsalicylic acid and the risk 
to develop AUR, what is probably due to the fact that acetylsalicylic acid was mainly used at a 
low cardio-protective dosage without anti-inflammatory activity. 
Despite the fact that we did find an association between the use of NSAIDs and risk of AUR 
in this population-based study, our results need to be interpreted with caution. Our exposure 
assessment was based on longitudinally collected GP prescriptions rather than dispensing 
or patient reported intake and did not include over the counter use. Therefore we may have 
misclassified at least some of the exposure to NSAIDs. However, it is likely that the exposure 
misclassification will be non-differential and thus the reported risk estimate will be an 
underestimate of the true risk estimate. To avoid misclassification of the outcome, we manually 
validated all cases and only included definite cases of AUR in our analysis. Additionally the 
physicians who reviewed and classified the cases were blinded to the patient’s drug exposure. 
Diagnostic bias will be limited since the first case reports on a possible association between the 
use of NSAIDs and AUR were only published in September 2002 and moreover a diagnosis of 
AUR is unlikely to be missed. 
Confounding by indication could be a concern in this study, as NSAIDs are used for the 
treatment of various urological conditions such as urinary tract infections and nephrolithiasis 
which by themselves could precipitate AUR.(16, 17) To control for confounding by indication, we 
checked the indication for all current use of NSAIDs in both cases and controls. Only one patient 
amongst the cases used NSAIDs for a urological condition (chronic prostatitis) and initiated 
this therapy months prior to the index date suggesting little or no influence of confounding by 
indication. The highest risk of AUR that was found amongst recent starters of NSAIDs is probably 
not confounded by indication as none of these cases used NSAIDs for urological conditions. 
As potential confounders we considered all known risk factors for AUR, but residual 
confounding by unknown risk factors for which we did not control may remain. Our study 
confirmed the association between AUR and the presence of known risk factors such as drugs 
with anticholinergic effects, use of narcotic analgesics and a history of BPH, prostate cancer, 
surgery, constipation, UTI, nephrolithiasis, cancer and home bound lifestyle.(18) The risk of AUR 
was not increased in patients with diabetes mellitus. However, we did find an association 
between AUR and patients with long lasting diabetes mellitus type 1 (OR matched 4.1 (95% CI 1.3-
13.5) when categorizing diabetes mellitus into type 1 or type 2. 
In conclusion, we found that the risk of AUR is about 2-fold higher in patients currently using 
NSAIDs compared to those not taking NSAIDs. 
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Abstract
Context: Acute urinary retention (AUR) is characterized by the sudden inability to urinate, which 
is usually painful and requires catheterization. 
Objective: To investigate whether the use of antipsychotic drugs is associated with an increased 
risk of AUR.
Design: Population-based case-control study.
Setting: Data from the Integrated Primary Care Information (IPCI) project in the Netherlands.
Participants: The source population comprised all males, 45 years or older, registered in the 
database between 1995 on through 2002. Cases were all men with a validated diagnosis of AUR. 
Each case was matched on age and calendar time with up to 10 controls.
Main outcome measure: Exposure to antipsychotic drugs in patients with AUR versus exposure 
to antipsychotic drugs in controls, using conditional logistic regression analysis with odds ratios 
(ORs) and 95% confidence intervals (CIs). 
Results: Within the source population of 72,114 men, we identified 536 cases of AUR and 5348 
matched controls. The risk of AUR was 4.02-fold (95% CI: 2.32-6.97) higher in current users of 
antipsychotic drugs. This increased risk remained after adjusting for all other known AUR risk 
factors (ORadj 2.62 [95%CI 1.37-5.02]). The highest risk for AUR (ORadj 8.1 [95% CI 1.7-38.3]) was 
observed in patients who recently (within one month prior to the index date) started using 
their antipsychotic drugs and in those using a higher daily dose. Amongst the antipsychotic 
drugs, there was a strong association between current use of phenothiazines or thioxanthenes 
and AUR.
Conclusion: The risk of AUR is 2.6 higher in patients using antipsychotic drugs than in non-
users.
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Introduction
Acute urinary retention (AUR) is a condition characterized by the sudden inability to urinate, 
which is usually painful and requires catheterization.1 The causes of AUR can be classified into 
three categories. The first category relates to any event that increases the resistance of the urinary 
flow such as benign prostatic hyperplasia (BPH). The second category involves interruption of 
either the sensory innervation of the bladder or weakness of the detrusor muscle. The third 
category relates to any situation that permits the bladder to over-distend (e.g. post surgery).2 
The incidence of AUR is higher in males than in females, especially in the older age categories, 
as males suffer more often from morbidities known to provoke AUR.3
AUR has been associated with the use of drugs that possess anticholinergic effects such 
as antipsychotics.2 The anticholinergic effect is caused by a blockade of the parasympathetic 
chain which may result in an inhibition of the contraction of the detrusor muscle and finally 
in AUR. The anticholinergic activity is not the same for all antipsychotics.4 Phenothiazines 
(mainly chlorpromazine and thioridazine) and thioxanthenes (mainly chlorprotixen) have a 
strong anticholinergic effect. Amongst the atypical antipsychotics, anticholinergic side-effects 
have been described for clozapine.5 Antipsychotic drugs are mainly used for the treatment 
of psychosis, but in the elderly, they are also prescribed to relieve symptoms of agitation and 
anxiety, especially in patients with Alzheimer’s disease.6 
The association between the use of antipsychotics and the risk of AUR is generally accepted, 
but to our knowledge, epidemiological studies to quantify this association have not yet been 
performed. Therefore we conducted a case-control study in a population of males, 45 years and 
older, to study the association between AUR and the use of antipsychotic drugs.
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Methods
Setting
This study was conducted in the Integrated Primary Care Information (IPCI) database in the 
Netherlands. The IPCI database is a general practice research database, containing information 
from electronic patient records of 150 general practitioners (GPs) covering more than 500,000 
patients. In the Dutch health care system, patients are registered with a single GP who acts 
as a gatekeeper of medical care and information.7 The electronic records contain coded and 
anonymous data on patient demographics, symptoms (using the International Classification 
for Primary Care (ICPC) and free text), diagnoses (using ICPC and free text), clinical findings, 
referrals, laboratory findings, and hospitalisations.8, 9 Summaries of the hospital discharge 
letters or information from specialists are entered in a free text format and hard copies can 
be provided upon request. Information on drug prescription comprises brand name, quantity, 
strength, indication, prescribed daily dose, the Anatomical Therapeutic Chemical classification 
(ATC) code and the physician linked indication.10 To maximize completeness of the data, GPs 
who participate in the IPCI project are not allowed to use paper-based records. The system 
complies with European Union guidelines on the use of medical data for medical research 
and has been proven valid for pharmaco-epidemiological research.11 The Scientific and Ethical 
Advisory Group of the IPCI project approved the study.
Source population
The source population comprised all males, 45 years of age or older with at least 6 months of 
valid database history. A valid history meant that the practice had been contributing data to 
the IPCI database for at least 6 months and that the patient had been registered with the GP for 
at least 6 months. This was required to have sufficient background information on all subjects. 
Follow-up started on January 1st 1995, the date at which 6 months of valid history was obtained 
or the date of the 45th birthday, whichever was latest. Patients having a history of AUR or radical 
cystectomy prior to study entry were excluded. All subjects were followed from study entry 
until the first episode of AUR, the end of the study period (December 2002), transferring out of 
the practice or death, whichever occurred first. 
Case identification and validation
AUR was defined as the sudden inability to pass any urine, requiring catheterization. All potential 
cases of AUR were manually reviewed by a physician (KMCV) and were categorized into 3 groups 
(definite AUR, possible AUR and no AUR). An endpoint committee consisting of 3 physicians 
(JLHRB, BS and MVW) reviewed all cases from the “possible AUR” category. Independently, the 
physicians classified the cases into 3 categories (“definite AUR”, “no AUR” or “AUR unknown”). If 
at least 2 of the 3 physicians agreed on a category, this category was assigned. If none of the 
physicians agreed, the AUR case remained within the “possible AUR” category. A sample of the 
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possible AUR cases (5%), assigned after the first validation, was in addition verified by the GP 
and the diagnosis was confirmed in 93% of all cases. 
Review of cases was blinded to drug exposure throughout the entire validation process. The 
index date was defined as the date of the first AUR. 
Controls
For each case we sampled up to 10 controls from the source population that was in follow-up 
at the time the case occurred. The controls were matched on age (year of birth) and calendar 
time (index date). 
Exposure definition
From the prescription records of cases and controls, all prescriptions for antipsychotic drugs 
prior to the index date were retrieved. Some of the antipsychotic drugs have a long serum half 
life and may be used as a depot product.5 Hence, exposure to antipsychotic drugs was classified 
as current if the last prescription covered the index date or ended within 1 month prior to the 
index date and as past if the end of the last prescription fell within 1 to 6 months prior to the 
index date. Subjects without a prescription within this period were classified as non-users. For 
current users of antipsychotic drugs, the effects of daily dose and the treatment-duration were 
studied. In order to aggregate dose of different drugs, daily dosages were expressed as Defined 
Daily Dose (DDD) equivalents. The DDD is the recommended average dosage of a drug for an 
adult for the main indication, as defined by the World Health Organization.10 The respective daily 
dosages of antipsychotic drug use were categorized into 4 categories based on the distribution 
of the DDDs in the controls. To study the effect of time since first antipsychotic drug use we 
categorized current users of antipsychotic drugs into recent starters if started within one month 
prior to the index date and long term users if started more than one month ago. To look at the 
effect of different types of antipsychotics, we distinguished 3 groups namely phenothiazines 
and thioxanthenes (which have the same pharmacodynamic and pharmacotherapeutic profile), 
butyrophenons and other (diphenylbutamines, tiapride and atypical antipsychotics). 
Covariates
Information on the presence of different risk factors for AUR was extracted from the compu-
terized patient records. These concerned current use of concomitant drugs knowing to cause 
AUR (drugs with anticholinergic effect, antidepressants, anti-Parkinson medication, narcotic 
analgesics, anxiolytics and non-steroidal anti inflammatory drugs); a recent (within 30 days prior 
to the index date) history of urinary tract infection (UTI), nephrolithiasis, constipation, surgery 
and home bound lifestyle. In addition, we checked for a history of BPH, prostate cancer, urine 
incontinence, diabetes mellitus, cardiac diseases, cancer (exclusive of prostate cancer), stroke, 
dementia and other neurological disorders prior to the index date. Finally, we identified the 
indication for antipsychotic drug use from the patient’s prescription records of current users.
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Statistical analysis
The incidence rate of AUR within this population was calculated by dividing the number of men 
with AUR by the number of men-years accumulated in the source population. 95% Confidence 
estimates were calculated around the estimates based on the Poisson distribution.
Conditional logistic regression analysis was used to assess the matched unadjusted and 
adjusted risk estimates for the association between risk factors and AUR and exposure to 
antipsychotic drugs and the occurrence of AUR. In the adjusted model we first included, one 
by one, all co-variates that were univariately associated with the outcome (p<0.05). Risk factors 
that changed the relative risk of AUR during current use of antipsychotic drugs by more than 5% 
were maintained in the final model. To estimate the proportion of AUR in the total population 
that can be attributed to current use of antipsychotic drugs, we calculated the Population 
Attributable Risk (PAR) using the following formula 12: 
 PAR= Attributable risk x proportion of exposed in the population
In this formula, the attributable risk is the incidence rate among the exposed minus the 
incidence rate among the unexposed and the proportion exposed is the proportion of current 
antipsychotic users among the controls. Data from the Dutch CBS (statline.cbs.nl) were used to 
extrapolate our results to the entire Dutch male population of 45 years or older.
All statistical analyses were conducted with the statistical software packages SPSS/PC 11.5.
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Results
Within the source population of 72,114 males of 45 years and older, we identified 536 definite 
and 25 possible cases of AUR. The incidence rate was 2.4 per 1000 men-years (95% CI 2.25-2.65 
per 1000 men-years). To avoid false-positive misclassification of the outcome, we only included 
definite cases in our case-control analyses. These 536 definite AUR cases were matched to 5348 
controls. The mean age of AUR cases was 73.0 years (SD 10.4). Cases had a higher prevalence of 
co-morbidity such as BPH, prostate cancer, neurological disorders and cancer and more often 
had a history of urinary tract infections, constipation, surgery and home bound lifestyle than 
controls (table 1). Current use of drugs with anticholinergic effects (excluding antipsychotics), 
narcotic analgesics, NSAIDs, anti-Parkinson medication and anxiolytics was also higher among 
the cases than among the controls (table 1).
Table 1: Patient characteristics and the univariate association with AUR
Cases Controls ORmatched* 95% CI
 (n=536) % (n=5348) %
Comorbidity
BPH 228 42.5 966 18.1 3.48 2.88-4.21
Prostate cancer 52 9.7 143 2.7 3.88 2.79-5.40
UTI 45 8.4 14 0.3 39.56 20.44-76.66
Urolithiasis 2 0.4 2 0.0 10.0 1.4-71.0
Urinary incontinence 22 4.1 105 2.0 2.15 1.34-3.46
Surgery 74 13.8 34 0.6 23.89 15.62-36.55
Constipation 22 4.1 23 0.4 9.83 5.44-17.76
Diabetes mellitus# 51 9.5 473 8.8 1.08 0.80-1.46
Cardiac diseases 176 32.8 1491 27.9 1.27 1.05-1.55
Stroke 38 7.1 255 4.8 1.54 1.08-2.20
Dementia 7 1.3 44 0.8 1.6 0.7-3.6
Neurological disorders 12 2.2 61 1.1 1.97 1.05-3.70
Cancer 39 7.3 165 3.1 2.48 1.72-3.56
Home bound lifestyle 159 29.7 476 8.9 5.43 4.30-6.86
Concomitant Medication
Use of anticholinergic drugs 34 6.3 235 4.4 1.49 1.03-2.16
Use of anticholinergic Parkinson 
medication
3 0.6 6 0.1 5.0 1.2-20.0
Use of narcotic analgesics 28 5.2 62 1.2 4.61 2.93-7.26
Use of antidepressants 16 3.0 116 2.2 1.41 0.83-2.39
Use of NSAIDs 28 5.2 131 2.4 2.26 1.49-3.45
Use of anxiolytics 69 12.9 430 8.0 1.76 1.34-2.32
* matched on year of birth and index date #risk of AUR was increased in patients with long lasting diabetes mellitus type 1 (OR matched 4.1 (95% CI 1.3-13.5))
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The unadjusted OR for AUR was 4.02 (95% CI 2.32-6.97) for current use of antipsychotic drugs 
compared to no use. Upon adjustment for other AUR risk factors the ORadj lowered to 2.62 (95% 
CI 1.37-5.02) (table 2). Past use of antipsychotic drugs was not associated with an increased risk 
of AUR. (ORadj 1.03 [95%CI 0.53-1.98]) 
The risk of AUR increased with increasing daily dose and the highest risk of AUR was observed 
in patients using antipsychotic drugs at a dose of 0.4 DDD or higher (Table 2). Also, the association 
with AUR was highest for patients who recently (within one month prior to the index date) 
started using antipsychotics and who were antipsychotic naïve (ORadj 8.1; 95% CI 1.7-38.3) 
(table 2). The risk was highest for patients currently using phenothiazines or thioxanthene. This 
increased risk remained after adjusting for the daily dose (ORadj 9.0, 95% CI 2.5-33.0) (table 3). 
Table 2: antipsychotic drug use and the risk of AUR
 AUR cases Controls ORmatched* (95% CI) ORadj # (95% CI)
(n=536) % (n=5348) %
Antipsychotic drugs
No use
Current use
Past use
503
19
14
93.8
3.5
2.6
5188
51
109
97.0
1.0
2.0
reference
4.02 (2.32-6.97)
1.32 (0.75-2.31)
reference
2.62 (1.37-5.02)
1.03 (0.53-1.98)
DDD of current use  
of antipsychotic drugs
No use
Current use
• ≤ 0.125 DDD
• > 0.125 DDD and ≤ 0.4 DDD
• > 0.4 DDD
Past use
503
7
6
6
14
93.8
1.3
1.1
1.1
2.6
5188
26
13
12
109
97.0
0.5
0.2
0.2
2.0
reference
2.9 (1.2-7.0)
5.0 (1.9-13.1)
5.1 (1.9-13.6)
1.32 (0.75-2.31)
reference
1.9 (0.8-5.0)
3.3 (1.0-10.8)
3.6 (1.1-12.3)
1.03 (0.53-1.98)
Duration of  
antipsychotic drugs
No use
Current use
• Started less than 1 month
• Started more than 1 month
Past use
503
7
12
14
93.8
1.3
2.2
2.6
5188
6
45
109
97.0
0.1
0.8
2.0
reference
13.7 (4.3-43.7)
2.9 (1.5-5.5)
1.31 (0.74-2.30)
reference
8.1 (1.7-38.3)
2.0 (0.96-4.3)
1.02 (0.53-1.97)
* matched on year of birth and index date # adjusted for BPH, UTI, incontinence, surgery, stroke, home bound lifestyle and use of antiparkinson medication and anxiolytics.
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Table 3: Risk of AUR by class of antipsychotic drugs
 AUR cases Controls ORmatched* (95% CI) ORadj # (95% CI) ORadj ¥ (95% CI)
(n=536) % (n=5348) %
Class antipsychotic 
drugs
No use
Current use of 
-  Phenothiazines or  
thioxanthenes
- Butyrophenons
- Others
Past use
503
13
5
1
14
93.8
2.4
0.9
0.1
2.6
5188
18
24
8
110
97.0
0.3
0.4
0.2
2.1
Reference
7.1 (3.5-14.6)
2.2 (0.8-6.0)
1.3 (0.2-10.6)
1.31 (0.75-2.31)
Reference
5.6 (2.3-13.9)
1.5 (0.5-4.3)
1.0 (0.1-8.4)
1.03 (0.53-1.98)
Reference
9.0 (2.5-33.0)
1.7 (0.6-5.1)
1.3 (0.1-11.2)
1.03 (0.53-1.98)
* matched on year of birth and index date # adjusted for BPH, UTI, incontinence, surgery, stroke, home bound lifestyle and use of antiparkinson 
medication and anxiolytics. ¥additionally adjusted for daily dosage.
To evaluate potential confounding by indication, we verified the indication for use of 
antipsychotic drugs and found that psychosis, which has been associated with AUR, was the 
indication for current use of antipsychotics in 2 out of the 19 cases (10.5%) compared to 7 out 
of the 51 controls (13.7%). 
We explored effect modification by age, recent urinary tract infection, a history of BPH, 
prostate cancer, use of concomitant medication such as anticholinergics or narcotics. We did 
not identify significant multiplicative effect modification by any of these variables.
Finally, based on an incidence rate of AUR of 6.19 per 1000 men-years amongst the exposed 
and an incidence rate of 2.36 per 1000 men-years among the unexposed, we calculated a PAR 
of 38.3/106/year. Using demographic data from the Dutch Central Bureau of Statistics (statline.
cbs.nl) and an overall AUR incidence rate of 2.36 per 1000 men-years in males 45 years and 
older, our data imply that for 1998, 1.6% of the AUR cases in men, 45 years and older could be 
attributed to current use of antipsychotics. 
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Discussion
In this study, we showed that current use of antipsychotics is associated with an increased 
risk of acute urinary retention (AUR). The risk is highest in patients who recently started 
using antipsychotics, those who use higher daily dosages and those who are treated with 
phenothiazines or thioxanthenes. These data are consistent with the expected anticholinergic 
effects of antipsychotics. To our knowledge, this is the first epidemiological study that quantifies 
this association. 
The association between AUR and antipsychotic drugs was the strongest for patients 
currently using phenothiazines or thioxanthenes, however, we could not distinguish between 
the individual products in these classes because of small numbers. Amongst the atypical 
antipsychotic drugs, anticholinergic effects have been described for clozapine and risperidone 
4, 5. We could not confirm an association between AUR and the use of clozapine and risperidone 
as none of the AUR cases were current users of any of these drugs. 
We did find that the association between the current use of antipsychotic drugs and AUR was 
highest for patients who were antipsychotic naïve until one month prior to the index date. This 
seems plausible as it is assumed that the risk of AUR is highest during initiation of antipsychotic 
treatment and declines following weeks of continuous treatment at an unchanged dose. 13
Despite the fact that we found an association between the use of antipsychotics and risk 
of AUR in this population-based study, our results should be interpreted with caution. Our 
exposure assessment was based on longitudinally collected GP prescriptions rather than 
dispensing or patient reported intake. Therefore we may have misclassified at least some of the 
exposure to antipsychotics. However, it is likely that the exposure misclassification will be non-
differential which implies that the reported risk estimate is an underestimate of the true risk. 
To avoid misclassification of the outcome, we manually validated all cases and only included 
definite cases of AUR in our analysis. Additionally the physicians who reviewed and classified 
the cases were blinded to the patient’s drug exposure. 
Confounding by indication could be a concern in this study as a possible association 
between psychosis (in schizophrenic patients) and urinary retention has been described in a 
case report.13, 14 In our study, there was a similar frequency of the indication “psychosis’ in cases 
and controls. Therefore, confounding by indication is unlikely. Antipsychotic drugs were mainly 
prescribed for the relief of symptoms such as anxiety, agitation, and insomnia in this population 
of ageing men. This also explains the low daily dosage. 
Protopathic bias might be a concern if treatment with antipsychotic drugs was started to 
relief the first symptoms of AUR (e.g. restlessness in ageing, dementing patients). To control 
for protopathic bias, we checked the treatment start date for both cases and controls and 
found that the antipsychotics were initiated at least one week prior to the index date. As AUR 
is an acute event, it is thus unlikely that the association was distorted by protopathic bias. 
Confounding by drugs, prescribed to reduce the adverse-effects of antipsychotics, could as well 
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be an issue in this study as extra-pyramidal symptoms (a common adverse-effect of the first 
generation of antipsychotic drugs) are commonly treated with anticholinergic, anti-parkinson 
drugs.15 Therefore, we adjusted for anticholinergic, antiparkinsonian drugs. 
Our study confirmed the association between AUR and the presence of known risk factors 
such as other drugs with anticholinergic effects, use of narcotic analgesics and a history of BPH, 
prostate cancer, surgery, constipation, UTI, urolithiasis, cancer and home bound lifestyle.16 
Some cases and studies (both in vitro and in vivo) reported on the occurrence of urinary in-
continence as opposed to AUR in patients on antipsychotic treatment, especially clozapine.17-19 
Psychosis by itself can be a direct cause of urinary incontinence, but the use of antipsychotic 
drugs might as well cause urinary incontinence via an inhibition of the dopaminergic (central) 
and alpha-adrenergic receptors (peripheral).20 Antipsychotics thus seem to be able to provoke 
as well as inhibit micturition and further research is warranted to study its mechanisms and its 
influencing factors. 
In conclusion, we found that the risk of AUR is more than 2.6 higher in patients currently 
using antipsychotic drugs compared to those not taking antipsychotic drugs. Although the 
population attributable risk was rather modest, physicians should be vigilant when prescribing 
antipsychotic drugs, especially in high-risk patients.
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General Discussion
8.1 Background
Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men and is present 
in more than 50% of men aged over 60 years. (1) BPH might cause lower urinary tract symptoms 
(LUTS) usually categorized into storage or voiding symptoms. Not all men with BPH will develop 
LUTS and LUTS by itself can also be caused by other urological conditions (e.g. urinary tract 
infections, detrusor instability) or other non-urological conditions such as heart failure and 
diabetes mellitus. (1) BPH is a progressive disease and may lead to serious medical conditions 
such as acute or chronic urinary retention, recurrent urinary tract infections and bleeding. (1-3)
The primary goals of treatment for BPH are to relieve the symptoms and to prevent 
progression. The different treatment regimens for men with LUTS/BPH consist of watchful 
waiting, pharmacological treatment or prostate surgery. The decision to opt for a specific 
treatment regimen is based on LUTS symptom severity and the patient characteristics such as 
age and medical conditions.(4, 5) 
The prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia 
(LUTS/BPH) varies between 4-25% depending on the LUTS/BPH definition used and the 
population studied. (6)
As little is known on the incidence of LUTS/BPH and the management of men with LUTS/
BPH in real life, we aimed to study the epidemiology and management of patients with 
symptomatic BPH using data from the International Primary Care Information (IPCI) project, a 
general practitioner’s database in the Netherlands. 
In this chapter, the most important findings are summarized and the study setting and related 
methodological considerations are clarified. In addition, the clinical implications of this research 
and potential for future research within the domain of LUTS/BPH are discussed. 
8.2 Main findings
8.2.1 Incidence and prevalence of LUTS/BPH
The prevalence of LUTS/BPH has been studied in detail in the past, but information on the 
incidence of LUTS/BPH is missing. 
The overall prevalence in our cohort of men 45 years or older was 10.3% and increased with 
age to a maximum prevalence of 24% at the age of 80 years. This prevalence falls within the 
prevalence rates that were reported in other studies. (7) (6, 8-12) In other studies the variation in 
prevalence is huge (lowest 4% - highest 56%), depending on the type of cohort studied, the 
geographic region, and the LUTS/BPH case definition. Data from two community-based studies 
in the Netherlands showed that the prevalence of LUTS/BPH indeed strongly depends on the 
case definition. In these studies, the prevalence decreased from a high prevalence of 20% to 
a lower prevalence of 4-9% when stricter criteria for case assessment were used. (12, 13) Ideally, 
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LUTS/BPH would be defined as a combination of LUTS (assessed via a symptom questionnaire), 
prostate size and uroflow-measurement. As we conducted a retrospective cohort study, 
information on urodynamical findings and I-PSS was often missing. Therefore, we had to use an 
alternative case definition and defined a case of LUTS/BPH if the patient expressed LUTS that 
could not be attributed to other (urological) conditions, if he was diagnosed by the urologist as 
having BPH or if he was treated for LUTS/BPH. 
The overall incidence of LUTS/BPH in our cohort of men, 45 years or older, was 15 per 1000 
man-years. The incidence was the lowest at the age of 45-49 (3 per 1000 man-years) and almost 
linearly increased with age until the age of 75-79 (38 per 1000 man-years). From the incidence 
data, we may expect that 45% of symptom-free men, aged 46 years will develop LUTS/BPH over 
the coming 30 years. 
The results on the incidence and prevalence of LUTS/BPH should be regarded as conservative 
estimates as only patients presenting themselves with symptoms of LUTS/BPH were considered. 
It is likely that the true incidence and prevalence of LUTS/BPH in the community is higher. 
A significant proportion of men may experience urinary symptoms but may be reluctant to 
visit their physician for fear of surgery or embarrassment, or may dismiss the symptoms as a 
mere consequence of ageing. Garraway et al. found that only half of the men with bothersome 
nocturia consulted a physician.(14) It is likely however, that such patients present themselves in a 
later stage of disease, when symptoms increase in severity.
8.2.2 Diagnostic work-up by general practitioners of patients with LUTS/BPH
Physical examination, including digital rectal examination, and urinalysis are mandatory 
examinations according to the Dutch GP guidelines on the management of voiding difficulties 
in older men.(15) Additional examinations are only recommended in specific circumstances such 
as urine culture in case of suspicion of urinary tract infections. As prostate-specific antigen (PSA) 
(a tumor marker in the detection and follow-up of prostate cancer) is often mildly elevated in 
patients with BPH, the Dutch guidelines only recommend use of PSA in patients younger than 
70 years and with a digital rectal examination that is difficult to interpret.(15, 16) In addition, there 
is no consensus about the further evaluation of patients with an abnormal PSA. We suspected 
that the frequency of PSA testing was much higher than recommended by the Dutch guidelines. 
A retrospective cohort study was conducted to investigate the frequency of PSA-testing, 
the management of patients with abnormal PSA results and whether PSA testing, as part of 
diagnostic work-up, had an impact on the incidence of prostate cancer during follow-up. 
PSA testing as part of diagnostic work-up took place in more than 50% of all patients with 
first LUTS/BPH. PSA turned out to be abnormal (PSA>4 ng/ml) in 30%. When only considering 
the patients with an abnormal PSA and at least 6 months of follow-up, 47% were immediately 
referred to an urologist and 23% had a repeat PSA-testing done, whereas no action was taken 
in approximately 30%. 
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These findings suggest that Dutch GP guidelines on the management of voiding difficulties 
in older men are not applied in daily practice. The fact that 30% of patients with an abnormal 
PSA result were neither referred to an urologist nor were tested again might indicate a lack 
on clear guidelines on follow-up of patients with abnormal PSA results. However, it could as 
well be a deliberate decision by the GP, based on the patient’s life expectancy, taking into 
account patient’s age and co morbidity. Other studies have shown as well that PSA testing 
was very common amongst patients with LUTS/BPH although local guidelines advised against 
the systematic use of PSA in the diagnostic work-up.(16, 17) Although none of these studies had 
information on the indication for PSA testing, the authors suggested that the decision on PSA 
testing was mainly influenced by a request from the patient, presence of symptoms suggestive 
of prostate cancer or potential concern about malpractice litigation.(16, 18) It might as well be 
a consequence of an overestimation of the diagnostic value of PSA in the early diagnosis of 
prostate cancer. 
We found information on digital rectal examination only in approximately 60% of all patients, 
despite the fact that this examination is mandatory according to the Dutch guidelines. (15) 
Although recording of digital rectal examination might have been omitted by the GP, it seems 
that it is not a popular tool in the differential diagnosis for men with micturition difficulties. The 
importance of DRE in the differential diagnosis of prostate cancer should not be neglected as 
we found that the prostate cancer detection rate was highest in patients referred for both a DRE 
suspicious for prostate cancer and an abnormal PSA.
8.2.3 Therapeutic management of patients with LUTS/BPH
Little is known about LUTS/BPH treatment and the related compliance in general practice. We 
studied the therapeutic management of patients with LUTS/BPH and the adherence to and 
persistence with pharmacological treatment. In addition, we studied the association between 
the type of LUTS/BPH complaints (voiding symptoms, storage symptoms, post-micturition 
symptoms) and the risk of early treatment discontinuation.(19) 
Approximately 50% of all LUTS/BPH patients received pharmacological treatment. Most 
patients received their first prescription for an α-blocker or a 5α-reductase inhibitor within 
one year after first symptoms. α-Blockers were the most frequently used first line treatment 
especially in the most recent years. Treatment is often intermittently used with large gaps 
between the prescriptions (overall adherence around 70%). Approximately 1 out of ten treated 
patients switched to a drug of another compound for reasons of adverse events, lack of efficacy 
or based on recommendations from the urologists. Treatment persistence was low and 26% 
of the patients discontinued treatment early after start mainly for reasons such as insufficient 
efficacy or adverse events. The risk of early treatment discontinuation was highest for patients 
with mainly voiding symptoms, younger age and less co-morbidity. 
The percentage of pharmacologically treated patients is quite low. This is in accordance 
with guidelines of the Dutch society of general practitioners on the management of voiding 
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difficulties in older men.(15) These guidelines advise watchful waiting for mild complaints 
and reserve pharmacological treatment for men with moderate to severe symptoms when 
other measures fail and surgery is contra-indicated. Also in accordance with these guidelines, 
treatment persistence is low, as guidelines suggest re-evaluation 6 weeks after the first 
prescription. If the drug proves to be effective, the treatment is continued for another 3 months 
and then discontinued. If symptoms re-appear, therapy is re-initiated.(15) The true adherence to 
and persistence with pharmacological treatment might even be lower, as the IPCI project only 
provides us with information on prescriptions. Therefore, we do not have information on drug 
dispensing nor on actual drug intake.
The overall incidence rate of prostate surgery was 62.0 per 1000 men-years. This incidence 
rate increased with age until the age of 75-79 years and declined in the higher age categories. 
The incidence rate of prostate surgery decreased over time with the lowest incidence in 2000. 
The incidence rate of prostate surgery and the age and calendar year pattern is similar to 
findings from other studies. (20-26) There seems to be a clear trend in postponing surgery and 
using pharmacological treatment as first option in patient with LUTS/BPH who do not respond 
to watchful waiting. Postponing prostate surgery might implicate that surgery occurs in high 
risk patients (older age categories with more co-morbidity) with larger prostates and more 
severe symptoms. This could jeopardize a positive outcome.(27)
8.2.4. Incidence of AUR
Information on the incidence rate of AUR in the general male population is available from 2 
large cohort studies in the US. The incidence rate of AUR in the Olmsted County was 6.8 per 
1000 man-years, whereas the incidence rate of AUR in the Health Professional Follow-up study 
was 4.5 per 1000 man-years. (28, 29) As information on the incidence rate of AUR in Europe is scarce, 
we performed a retrospective cohort study in the IPCI database. 
Amongst a population of almost 57,000 males, 45 years or older, we identified 344 first cases of 
AUR resulting in an overall incidence rate of AUR of 2.2 per 1000 man-years, increasing with age. 
This incidence rate is thus lower than the incidence rate as reported by the US cohort studies. 
However, this could be attributed to differences in case definition and selection bias in the US 
studies. In both the Olmsted county and the Health Professional Follow-up study, participants to 
the AUR study were selected based on the completion of a questionnaire asking for urological 
complaints or conditions. This is supported by the fact that the prevalence of LUTS/BPH is much 
higher in the US cohort studies than in ours. In the Health Professional study, patients were 
asked by mail if they had experienced an episode of AUR requiring urinary catheterization 
whereas we, similar to what was done in the Olmsted County, reviewed the patient records 
for the occurrence of AUR requiring catheterization. Our estimates provide population based 
incidence rates and do not suffer from selection bias.
In addition we studied a sub-cohort of patients newly diagnosed with LUTS/BPH. Within this 
cohort, we identified 149 new cases of AUR. Strikingly, almost 50% of AUR cases entered the 
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cohort with AUR as first symptom of BPH. If we excluded these patients, the overall incidence 
rate of AUR was 18.3 per 1000 man-years and increased with age. The risk of developing AUR 
was 11-fold higher in men newly diagnosed with LUTS/BPH. 
We know from recent randomized controlled trials that pharmacological treatment, and 
especially the combination of an α-blocker with a 5α-reductase inhibitor, might prevent BPH 
progression.(30-32) However, in order for prevention to be effective, earlier LUTS/BPH identification, 
especially in patients at risk for AUR, seems to be important. 
8.2.5 Risk factors for AUR
We investigated, by means of a case-control study, if certain classes of medications are associated 
with an increased risk of AUR. From the literature, we know that almost 50% of AUR cases in 
men are associated with BPH, however, AUR might also be precipitated by other factors such as 
urinary tract infections or preceding surgery.(33, 34) For this reason, the study population was not 
restricted to men with BPH but included all men, 45 years or older. 
In our case-control study, we demonstrated that the risk of AUR was about 2-fold higher in 
current users of NSAIDs and 2.6 higher in current users of antipsychotic drugs. For both NSAIDs 
and antipsychotic drugs, the risk was the highest in the higher dosage categories, or in patients 
who recently started using these drugs. Also the current use of other anticholinergic drugs and 
narcotic analgesics were associated with AUR. In addition, we confirmed known risk factors for 
AUR such as BPH, surgery, constipation, urinary tract infection and immobility. (33, 34)
The act of micturition is a very complex mechanism (see chapter 1) and the above-mentioned risk 
factors act via different pathways. All kinds of neurotransmitters and mediators interfere with 
micturition. Acetylcholine, which interacts with muscarinic receptors on the detrusor muscle, is 
the predominant peripheral neurotransmitter responsible for bladder contraction. Dopamine 
and serotonine are central neurotransmitters and are involved in the regulation of the 
micturition reflex. Serotonergic activity facilitates urine storage by enhancing the sympathetic 
reflex pathway and inhibiting the parasympathetic voiding pathway. Dopaminergic pathways 
may exert both inhibitory and facilitatory effects on voiding. D1 receptors appear to have a role 
in suppressing bladder activity, whereas dopamine D2 receptors appear to facilitate voiding.(35-
38) 
The distention of the bladder evokes afferent activity via myelinated Aδ fibers. In addition, 
the distention of the bladder causes the urothelium to release all kind of transmitters (ATP, 
tachykinins, NO and prostaglandin E2 (PGE2)) that interfere with micturition via the afferent 
pathway. ATP, tachykinins and PGE2 have a stimulating effect on micturition, whereas NO has an 
inhibitory effect on micturition. (38-40)
PGE2 in the bladder is synthesized via cyclooxygenase-2 and is up-regulated by a number of 
stimuli such as inflammation, trauma and over-distention. (40)
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Results of our case-control study showed an association between current use of NSAIDs and 
the risk of AUR. Based on the various mechanisms as described above, this seems plausible as 
NSAIDs inhibit the formation of PGE2 resulting in relaxation of the detrusor muscle. 
Some of the antipsychotic drugs have a strong anticholinergic effect. (41) This anticholinergic 
effect results in the inhibition of the parasympathetic chain, hindering the contraction of the 
detrusor muscle. Incontinence has also been described in patients using antipsychotic drugs 
via their direct effect on the dopamine receptors and the α-receptors. (42, 43)
8.3 Methodological considerations
8.3.1 Study setting
All reported studies used data from the Integrated Primary Care Information (IPCI) project in the 
Netherlands. The IPCI database is a longitudinal observational database that contains information 
from computer-based records of more than 150 GPs in the Netherlands. Information is available 
from approximately 500,000 patients and consists of detailed data on patient demographics, 
symptoms, diagnosis, lab results, referrals, drug prescription and hospitalizations. (44, 45)
Using data from the IPCI project was essential to study the incidence rates of LUTS/BPH and 
AUR in a population of ageing men for the following reasons. Firstly, we had access to a very 
large population of men that were followed over time. Secondly, the potential for selection bias 
(see 8.3.3) was negligible as participation in the IPCI project is based on passive consent and thus 
most patients contribute data. In addition, as the IPCI project contains the complete medical 
records of all patients, it gave us good insight into the patient characteristics, co-morbidity and 
treatment of patients with LUTS/BPH. However, as data was collected retrospectively, some 
crucial information on symptom severity, urinary catheterization, prostate surgery, prostate 
biopsy and prostate cancer staging was sometimes missing. In these circumstances, the 
GPs were contacted by letter to request additional information and a copy of the discharge 
or specialist letter if available. In addition, not all data in the IPCI database was coded which 
made the patient validation very labor-intensive. Finally, as the IPCI database is not linked to 
a pharmacy database, we did not have information on drug dispensing. Neither did we have 
information on “over-the-counter” use or actual drug intake. This might implicate that we have 
under- or overestimated pharmacological treatment. 
8.3.2. Study design
Our research on the epidemiology and management of symptomatic BPH used descriptive and 
analytical epidemiological techniques. Descriptive epidemiology focuses on the occurrence 
and risk factors for the disease in a population.(46) Descriptive epidemiological studies were 
designed to explore the incidence of LUTS/BPH, prostate surgery, and AUR. In addition, we used 
descriptive epidemiology to study the diagnostic work-up and the therapeutic management of 
patients newly diagnosed with LUTS/BPH. 
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If the aim of the research is to investigate the determinants of the disease, analytical 
epidemiological designs are used. (46, 47) Analytical studies can be divided into observational or 
intervention studies (clinical trials). In observational studies, the natural course of the events, in 
relationship to the exposure of interest are studied. There are two basic types of observational 
studies namely the case-control and the cohort studies. Both designs were used in our research 
on the epidemiology of symptomatic BPH and will be described briefly. 
Cohort study
In cohort studies, subjects are classified on the basis of the presence or absence of exposure to a 
particular factor and then followed for a specified period of time to determine the development 
of disease in each exposure group. Cohort studies are best suited to investigate relatively 
common outcomes. In retrospective cohort studies, all relevant events have occurred when the 
study is initiated. In prospective studies, the relevant exposures may or may not have occurred 
at the time the study started, but the outcomes have certainly not yet occurred. 
In general, prospective cohort studies are expensive and labor intensive, as they require 
a large sample size and a long follow-up before results are known. This is of less concern in 
retrospective cohort studies, as all relevant outcomes have already occurred at the time the 
study is initiated. However, as retrospective studies rely on data entered in the past, and this 
data is generally not entered for the purpose of epidemiological research, crucial information 
on exposure, co-morbidity and potential confounding factors may be missing. (46-48)
We retrospectively defined a disease specific cohort of men, newly diagnosed with LUTS/BPH 
to study the risk factors for pharmacological treatment, early treatment discontinuation and 
AUR. In addition, as part of our descriptive epidemiological approach, we used this design to 
study the diagnostic work-up of patients with LUTS/BPH and the different treatment regimens 
they received.
Case-control study
In a case-control study, a case group of patients who have the disease of interest and a control 
group of individuals without the disease, at the time of case occurrence, are selected and the 
odds of exposure in each group are compared. The case-control design is particularly efficient 
for investigation of relatively rare diseases, since it selects a group of individuals that have 
already developed the outcome. Case-control studies offer the advantage to study associations 
quickly and allow for the study of multiple exposures at the same time. However, as both disease 
and exposure have already occurred at the time of study start-up, case-control studies might 
be more vulnerable to bias such as information and/or selection bias. (see 8.3.3) (49) These arguments 
apply to de novo initiated case-control studies. In a database as IPCI, exposure and disease are 
registered prospectively and therefore, information bias is non-differential. Also, due to the 
possibility to choose either a cohort or a case-control design, arguments such as complexity of 
exposure become important design items. 
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8.3.3 Internal and external validity
The validity, or the degree to which a result is likely to be true, is very important, not only in 
epidemiological research. Commonly, two aspects of validity are considered namely the internal 
and the external validity. 
The internal validity of a study refers to the integrity of the experimental design – i.e. the 
ability to measure what it sets out to be measured. (50)
Bias (selection bias, information bias and confounding) undermines the internal validity of 
epidemiological research. (46-48, 51)
Selection bias
Selection bias results from an absence of comparability between the groups that are being 
compared due to differential participation rates. (46-48, 51)
An important form of selection bias is referral bias where patients voluntary refer themselves 
to take part in epidemiological research. Since the reason for self referral may be associated 
with the outcome under study, self referral of participants is generally considered as being a 
threat for the internal validity. As the IPCI data encompasses the total population and the data 
is gathered prospectively, without knowledge of the later formulated research questions, the 
magnitude of selection bias is negligible.
Diagnostic bias or detection bias is a type of selection bias and would occur if the diagnosis of 
the outcome (AUR in our research) would be influenced by knowledge of the exposure. We call 
it selection bias, although some experts in the field consider it as information bias. Diagnostic 
bias was not a concern in the case control study, investigating the relationship between the 
use of NSAIDs and AUR, as the first case reports on AUR in relation to the use of NSAIDs were 
only published in 2002.(52) Diagnostic bias might have influenced the study on the association 
between AUR and the current use of antipsychotic drugs as the anticholinergic side effects of 
antipsychotic drugs are well established. However, as AUR is an acute event, with unmistakable 
symptoms (the sudden inability to micturate in combination with abdominal pain and relief on 
catheterization), it is unlikely to be missed or to be incorrectly diagnosed. (33)
Information bias
Information bias, also known as observation, recall or (mis)-classification bias, results from an 
incorrect determination of exposure or outcome.(51) This information bias might be random 
(non-differential) or systematic (differential). 
Non-differential misclassification bias generally shifts the risk towards 1, whereas differential 
misclassification may result in over as well as an underestimation of the actual risk. (47, 48)
To avoid misclassification of the AURs, we manually validated all cases, and only included 
definite cases of AUR in our analysis. In addition, the physicians who reviewed and validated 
the patients were blinded to the patient’s exposure. Despite these measures, some random 
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misclassification of the outcome might have occurred which tends to underestimate rather 
than to overestimate the risk. 
Crucial in our case-control study on the association between use of concomitant drugs and 
risk of AUR was the assessment of drug exposure. Since our exposure assessment was based on 
longitudinally collected GP prescriptions, rather than dispensing records or patient reported 
intake, we might have misclassified some of the exposure. In addition, our exposure assessment 
did not include over-the-counter use. Lack on information on over-the-counter use might have 
had some influence on the case-control study on current use of NSAIDs and risk of AUR, as in the 
Netherlands, over-the-counter preparations with some low dose NSAIDs are available. However, 
the risk of AUR in current users of NSAIDs was associated with dose and was not elevated in 
low dose NSAID users. Therefore missing information on low dose NSAIDs was probably of less 
concern. Finally, our exposure assessment did not include the drugs prescribed by the specialist. 
Because of the health care system in the Netherlands, patients are usually referred back to the 
general practitioner who will be responsible to continue further prescriptions.
Overall, we may have at least misclassified some of the exposure. However, it is likely that 
the exposure misclassification was non-differential and therefore the reported association 
estimates are an underestimate of the true risk. 
Confounding
Confounding is one of the major concerns in epidemiological research, as it is one of the most 
difficult biases to detect and to control for. According to Webster’s comprehensive dictionary 
of the English language, confounding means confusing or mingling (elements, things or ideas) 
indistinguishably. (53)
A confounding variable is a variable that can cause the disease under study and is also 
associated with the exposure of interest. There are three criteria for a variable to be a confounder: 
it must be a risk factor for the disease (also in the non-exposed), it must be associated with 
the exposure (also in the non-diseased) and it must not be an intermediate step in the causal 
pathway. (figure 1) (46-48, 51)
Figure 1: Confounding factor in relationship to exposure and disease
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Confounding can lead to an over- or underestimation of the true association between exposure 
and outcome, depending on the direction of the associations which the confounding factor has 
with exposure and outcome.
Confounding can be controlled for via restriction, matching, stratification or multivariate 
techniques (e.g. mathematical modeling via multivariate logistic regression of proportional 
hazard analysis). (47, 51)
With restriction, the control of confounding is achieved by selecting into the study only 
individuals with certain homogeneous levels of the potential confounders. Matching involves 
removing the effect of the confounder by making the case group and the control group 
equivalent regarding the confounder.(46, 47, 51) Both techniques were applied in the case-control 
study as we restricted our population to men, 45 years or older, and we matched on age and 
index date.
In studies of pharmacologic therapies, confounding by indication may arise when the 
indication for the treatment is a risk factor for the outcome under study. (54, 55) Confounding by 
indication was definitely a concern in the case-control study on AUR and the use of NSAIDs. 
NSAIDs are used for the treatment of various urological conditions such as urinary tract 
infections and urolithiasis which by themselves could precipitate AUR. The same problem was 
encountered in the case-control study on AUR and the use of antipsychotic drugs because 
psychosis, which is one of the indications for the use of antipsychotic drugs, can by itself 
provoke AUR. 
To control for confounding by indication, we checked the indication for current use of NSAIDs 
and antipsychotic drugs in both cases and controls. Only one patient among the cases used 
NSAIDs for a urological condition (chronic prostatitis) and initiated this therapy months prior 
to the index date suggesting little or no influence of confounding by indication. The main 
indication for the use of NSAIDs, both in the cases and the controls, was osteoarthritis. The 
proportion of patients with psychosis was not higher amongst the cases (10.5%) than among 
the controls (13.7%), again suggesting negligible confounding by indication. Agitation was the 
main indication for use of antipsychotic drugs, both in cases and controls.
Protopathic bias occurs when a pharmacological agent is prescribed for an early manifestation 
of a disease that has not been diagnosed yet.(56) We investigated the potential for protopathic 
bias in the case-control study on use of NSAIDs and AUR, as NSAIDs might have been prescribed 
for the relief of abdominal pain which by itself could be the first symptom of AUR. However, as 
AUR is a very acute event that is unlikely to be missed and NSAIDs use on the index date was 
excluded, protopathic bias seems unlikely. Also, we checked the indication for current use of 
NSAIDs and none of the cases used NSAIDs for abdominal pain. 
External validity of epidemiological research implies that the observed findings can 
be generalized to the general population. External validity can be an issue in randomized 
controlled trials as participating patients tend to be different from patients who wish or can not 
participate due to stringent in- and exclusion criteria. (51)
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As we used data from the IPCI project, a GP research database containing information from 
more than 500,000 patients, we believe that our findings can be extrapolated to the general 
population of men, aged 45 years or older. 
8.4 Clinical implications
In the study on the diagnostic work-up of patients with LUTS/BPH we showed that PSA testing 
was done in more than 50%, that no further action was taken in 30% of patients with an 
abnormal PSA result and that digital rectal examination seems to be unpopular as information 
on digital rectal examination was only recorded in approximately 60% of all cases. It seems 
that real life practice differs from what is recommended by the current guidelines of the Dutch 
Society of General Practitioners on voiding difficulties in older men. Although we agree with 
the PSA restrictions as outlined in the Dutch guidelines, further clarification on the need, the 
interpretation and the follow-up of PSA testing in patients with LUTS/BPH might be desirable. 
In addition, it might be interesting to investigate why daily practice differs from what is outlined 
in the Dutch guidelines. Currently, the medical society is getting conflicting messages that on 
the one hand promote PSA testing in all patients with BPH to identify the ones that are likely 
to progress and on the other hand doubt the value of normal PSA results (≤ 4 ng/ml) to rule 
out prostate cancer. (57, 58) We also believe that the importance of digital rectal examination in 
the differential diagnosis of patients with LUTS/BPH should be re-emphasized. First of all, DRE 
is a relative simple test and secondly, studies, including our own; have shown that the positive 
predictive value improves for a combination of an abnormal DRE and an abnormal PSA. (59, 60)
In the study on the treatment strategies, the patterns of drug use and the treatment 
discontinuation in men with LUTS/BPH, we demonstrated that treatment adherence and 
treatment persistence was quite low. Patients should be informed about the importance of 
regular drug intake especially when using α-blockers as they have a shorter half-life and require 
regular intake. (41) Compliance is also important in patients using 5α-reductase inhibitors as 
prostate volume returns to the volume at start of therapy when treatment is discontinued for 
a long time.(41)
Results from some recent large randomized controlled trials with long term follow-up have 
shown that treatment with 5α-reductase inhibitors or the combination of an α-blocker with 
a 5α-reductase inhibitor might prevent BPH progression and complications such as prostate 
surgery, AUR, UTI or renal insufficiency.(30-32) In the cohort of newly diagnosed LUTS/BPH patients, 
half of AUR cases presented with AUR as the first symptom of LUTS/BPH. These patients would 
not have benefited from preventive pharmacological treatment as they were diagnosed too late. 
This could have several causes such as absence of prior LUTS/BPH symptoms, underreporting 
of symptoms by the patient or failure by the GP to recognize LUTS/BPH symptoms. Increasing 
both physician’s and patient’s awareness about the symptomatology, natural evolution and 
treatment of LUTS/BPH might be warranted. 
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Finally, we observed a positive association between the occurrence of AUR and the concurrent 
use of NSAIDs or antipsychotic drugs. Although the population attributable risk was rather 
modest, physicians should be informed about the possibility of provoking AUR in patients 
using NSAIDs and antipsychotic drugs. Especially in high-risk patients, careful prescribing 
seems justified. 
8.5 Future research
For efficiency reasons, we restricted our research on the incidence and risk factors for AUR to a 
population of men, 45 years or older. It might be interesting to extend our research to females 
as, to our knowledge, information on the incidence rate of AUR in females is lacking. Especially 
younger females are at risk of developing AUR, as childbirth and pregnancy are known risk 
factors for urinary retention in females. (34, 61)
Our case-control study on the association between AUR and use of NSAIDs or antipsychotic 
drugs was not able to detect effect modification. It seems plausible that the risk of AUR in 
patients using NSAIDs or antipsychotic drugs will be highest in AUR-risk groups (e.g. patients 
with BPH, older age, use of concomitant drugs knowing to provoke AUR). Further research on 
the presence of effect modification seems warranted.
Recent randomized controlled trials have shown that 5α-reductase inhibitors and especially 
the combination of an α-blocker with a 5α-reductase inhibitor are effective in the prevention 
of BPH progression. (30-32) However, these data result from randomized controlled trials that do 
not necessarily reflect real practice as they use stringent in-and exclusion criteria. So far, few 
population-based studies have examined the long-term effectiveness of BPH-treatment. (62, 
63) A population-based study investigating the long-term effects of BPH treatment would be 
feasible in the IPCI database. However, one of the main shortcomings when doing retrospective 
research in the domain of urology is the impossibility to categorize LUTS/BPH as information on 
symptom severity is often missing. Conducting a pragmatic trial might be the solution, however 
further experience and research on the feasibility of pragmatic trials is first needed.(64)
Use of α-blockers and 5α-reductase inhibitors has been associated with severe adverse events 
such as ischemic events in the former and breast cancer in the latter. (65, 66) We aim to explore the 
safety of these drugs in future research. This research however, will be complex as it will require 
sufficient follow-up and it will be vulnerable to all kinds of bias and confounding, especially 
diagnostic bias and confounding by indication. (67, 68) Also in the Netherlands, we might lack the 
power to study the safety of 5α-reductase inhibitors as the proportion of patients using these 
drugs decreased over time to only 2% of patients newly diagnosed with LUTS/BPH in 1999. 
The positive results of the MTOPS trial and the marketing of the newer 5α-reductase inhibitor, 
dutasteride, might increase the number of patients on 5α-reductase inhibitors which might 
allow studying rare events. (32, 41)
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Summary
Benign prostatic hyperplasia (BPH) is a common medical condition, especially in ageing 
men. BPH might become symptomatic resulting in lower urinary tract symptoms generally 
categorized into voiding or storage symptoms.
The aim of this thesis was to study the epidemiology and the management (in terms of 
diagnosis and therapeutic options) of symptomatic BPH. In addition we studied the incidence 
rate and the risk factors for AUR, a common complication in patients with BPH.
Chapter 1 provides a brief overview of BPH and its etiology, diagnosis and treatment. The 
incidence and prevalence of LUTS/BPH was estimated and is described in chapter 2. Within the 
IPCI database we defined a retrospective cohort study of all men, 45 years or older during the 
study period (1995-2000). Cases of LUTS/BPH were defined as persons with a diagnosis of BPH, 
treatment or surgery for BPH or urinary symptoms that could not be explained by other co-
morbidity. In the study cohort, 2181 incident and 5605 prevalent LUTS/BPH cases were identified. 
This resulted in an overall incidence rate of LUTS/BPH of 15/1000 man-years. The incidence of 
LUTS/BPH almost linearly increased with age with the lowest incidence (3/1000 man-years) at 
the age of 45-49 years and the highest at the age of 75-79 years (38/1000 man-years). From the 
cumulative incidence, we calculated the risk to develop LUTS/BPH for symptom-free men. For 
a symptom-free man at the age of 46 years, the risk to develop LUTS/BPH over the coming 10, 
20 or 30 years was 5, 20 or 45% respectively. The overall prevalence of LUTS/BPH was 10.3% and 
also increased with age with a maximum at the age of 80 years. 
In chapter 3, we describe the diagnostic work-up of patients with LUTS/BPH in terms of use 
of PSA testing. In a cohort of 1917 men, newly diagnosed by the general practitioner as having 
LUTS/BPH, PSA testing was performed in 1073 patients (55%). PSA turned out to be abnormal 
(PSA>4 ng/ml) in 319 patients. We followed the patients with an abnormal PSA who had at least 
6 months of follow-up (n=277) and found that follow-up actions (referral to an urologist or 
repeat PSA testing) were taken in approximately 70% and thus no follow-up action was taken 
in approximately 30%. Although mandatory according to the Dutch GP guidelines on difficult 
micturition in men, information on digital rectal examination was only recorded in 63% of all 
cases. Among the referred patients, the prostate cancer detection rate was highest in patients 
referred for an abnormal DRE in combination with an elevated PSA (HRadj 9.8; 95% CI 4.5-21). 
In chapter 4, the different treatment regimens and compliance issues, such as adherence, 
persistence and early treatment discontinuation, in patients newly diagnosed with LUTS/BPH 
were studied. Approximately 50% of all patients were pharmacologically treated, and α-blockers 
were the most frequent first line treatment, especially in the most recent years. Treatment 
persistence (37%) and treatment adherence during use (70%) was low and 26% of the treated 
patients discontinued their treatment early after treatment start. Risk factors for early treatment 
discontinuation were normal PSA levels, younger age and a lower chronic disease score. Patients 
with a combination of voiding, post-micturition and storage symptoms had the lowest risk for 
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treatment discontinuation. During follow-up, 10% of all patients underwent prostate surgery 
resulting in an overall incidence rate of 62/1000 man-years. The incidence rate of prostate 
surgery declined over time.
We described the incidence rate of AUR both in the general population of men, 45 years or 
older, and in the population of men newly diagnosed with LUTS/BPH in chapter 5. The incidence 
rate of AUR in the general population was quite low namely 2.2/1000 man-years. Of the 344 
AUR cases, more than 40% were precipitated by events such as general anesthesia, urinary tract 
infections and ingestions of drugs knowing to cause AUR. Hundred and forty nine cases of AUR 
were identified amongst the 2214 patients newly diagnosed with LUTS/BPH. AUR was the first 
presenting symptom of LUTS/BPH in almost half of these AUR cases. When excluding these 
cases from the analysis, the incidence rate of AUR in patients with newly diagnosed LUTS/BPH 
was 18.3/1000 man-years. When all AUR cases were included, the overall incidence rate was 
much higher (36/1000 man-years). The incidence rate of AUR increased with age, both in the 
general population and in the population of men, newly diagnosed with LUTS/BPH. 
Chapters 6 and 7 describe the results from a case-control study investigating the concomitant 
use of NSAIDs and antipsychotic drugs, as risk factor for AUR.
Within a population of men, 45 years or older, during the study period from 1st January 1995 
until 31st December 2002, 536 definite cases of AUR were identified. To these cases, 5348 random 
controls were matched on age and calendar time. The risk of AUR was 2 fold higher in current 
users of NSAIDs relative to no use. The risk was the highest in patients using higher NSAID 
dosages and in those who recently started using NSAIDs. The association between AUR was 
even stronger for current use of antipsychotic drugs, which increased the risk 2.6 fold. Here as 
well, the risk was the highest for patients who recently started using their antipsychotic drugs 
and in those who used higher dosages. 
In the general discussion (chapter 8), the main findings of the studies in this thesis and the 
methodological aspects are discussed. In addition, the clinical relevance of the findings and the 
potential for future research are considered.
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Samenvatting
Benigne prostaat hyperplasie (BPH) is een aandoening die vaak voorkomt bij de verouderende 
man. BPH kan zich uiten in mictie klachten, die vaak worden onderverdeeld in klachten van 
obstructieve of van irritatieve aard.
De bedoeling van het onderzoek in dit proefschrift was om de epidemiologie en het beleid (wat 
betreft diagnostiek en behandeling) van symptomatische BPH nader te bestuderen. Daarnaast 
werd ook de incidentie van acute urinaire retentie (AUR), en de mogelijke risicofactoren voor 
het optreden van AUR nader bestudeerd.
Hoofdstuk 1 geeft een algemeen overzicht van BPH waarbij met name de etiologie, de 
diagnostiek en de behandeling worden besproken. In hoofdstuk 2 werden de incidentie en de 
prevalentie van symptomatische BPH bestudeerd. Binnen de IPCI database werd een retrospectief 
cohort gedefinieerd van alle mannen van 45 jaar of ouder. Binnen dit cohort werd gedurende de 
studieperiode van 1995-2000, gezocht naar mannen met mictie klachten, suggestief voor BPH. 
Om aan dit criterium te voldoen dienden mannen gediagnosticeerd en/of behandeld te zijn 
voor BPH of mictie klachten te hebben, die niet waren toe te schrijven aan andere co-morbiditeit. 
Binnen het cohort werden 2181 incidente en 5605 prevalente gevallen van symptomatisch BPH 
geïdentificeerd. Dit resulteerde in een incidentie van symptomatisch BPH van 15/1000 man-jaren. 
Die incidentie nam bijna lineair toe met de leeftijd. De incidentie was het laagst op de leeftijd 
van 45-49 jaar (3/1000 man-jaren) en het hoogst op de leeftijd van 75-79 jaar (38/1000 man-
jaren). Aan de hand van de cumulatieve incidentie werd het risico op het ontwikkelen van mictie 
klachten passend bij BPH berekend. Voor een 46-jarige man zonder mictieklachten bedraagt 
het risico op het ontwikkelen van symptomatisch BPH gedurende de volgende 10, 20 of 30 jaar, 
respectievelijk 5, 20 en 45%. De prevalentie van symptomatisch BPH bedroeg 10.3% en nam ook 
toe met de leeftijd tot een maximale prevalentie op de leeftijd van 80 jaar. 
In hoofdstuk 3, wordt aandacht besteed aan de diagnostiek van mictieklachten passend 
bij BPH, met name wat betreft het gebruik van de serumspiegel van prostaat specifiek antigen 
(PSA). In een cohort van 1917 mannen, door hun huisarts voor de eerste keer gediagnosticeerd 
met symptomatische BPH, ondergingen 1073 mannen (55%) een PSA analyse in het kader van 
diagnostiek. PSA was verhoogd (>4 ng/ml) bij 319 mannen. De mannen met een afwijkend PSA 
en ten minste 6 maanden follow-up (n=277) werden verder gevolgd. Hieruit bleek dat bij 70% 
maatregelen genomen werden, in de vorm van een verwijzing naar de uroloog of herhaling 
van de PSA analyse. Bij 30% werden geen verdere maatregelen genomen. Ondanks het feit dat 
de NHG standaard rond de bemoelijkte mictie bij oudere mannen, stelt dat een rectaal toucher 
deel uit maakt van het standaard lichamelijk onderzoek, werd informatie rond het rectaal 
toucher slechts teruggevonden bij 63% van alle mannen. Binnen de verwezen patiënten, was 
het risico op prostaat kanker het hoogst bij patiënten die verwezen werden omwille van een 
afwijkend rectaal toucher in combinatie met een verhoogde PSA waarde (Relatieve risico 9.8; 
95% betrouwbaarheids interval (BI) 4.5-21).
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In hoofdstuk 4 worden de verschillende behandelingen voor symptomatische BPH en 
aspecten zoals therapietrouw en vroegtijdig stoppen van therapie besproken. Ongeveer 50% 
van alle patiënten, voor de eerste keer gediagnosticeerd met symptomatische BPH werden 
gedurende de follow-up farmacotherapeutisch behandeld. Er werden voornamelijk α-blockers 
voorgeschreven, vooral op het einde van de studieperiode. De continuiteit van de behandeling 
en de therapietrouw van de gebruikers was laag en 26% van de patiënten stopten vroegtijdig 
met hun therapie. Risicofactoren voor vroegtijdig stoppen waren normale PSA waarden, een 
jonge leeftijd en een lage morbiditeitsscore. Het risico op vroegtijdig stoppen was het laagst 
voor mannen met een combinatie van irritatieve, obstructieve en/of post-mictie klachten. 10% 
van de mannen ondergingen een prostaat chirurgie gedurende de follow-up resulterend in 
een incidentie van 62 gevallen van prostaat chirurgie per 1000 man-jaren. De incidentie van 
prostaatchirurgie nam af over de verschillende kalenderjaren. 
De incidentie van AUR, zowel in de totale populatie van mannen, ouder dan 45, als in de 
populatie van mannen, die voor de eerste keer gediagnosticeerd werden met symptomatische 
BPH wordt beschreven in hoofdstuk 5. De incidentie van AUR in de totale populatie was laag, 
namelijk 2.2 gevallen van AUR per 1000 man-jaren. In meer dan 40% van de 344 gevallen van AUR 
werd de retentie voorafgegaan door mogelijk uitlokkende factoren zoals anesthesie, infecties 
van de urinewegen en inname van bepaalde geneesmiddelen. Binnen het cohort van 2214 
mannen, voor de eerste keer gediagnosticeerd met symptomatisch BPH, traden, gedurende de 
studie periode, 149 gevallen van AUR op. AUR was de eerste uiting van symptomatische BPH 
bij ongeveer de helft van de gevallen. Wanneer die patiënten uit de analyse werden gesloten, 
bedroeg de incidentie van AUR 18 per 1000 man-jaren. Die incidentie was veel hoger, wanneer 
alle 149 gevallen van AUR in de analyse werden betrokken, namelijk 36 per 1000 man-jaren. In 
beide cohorten nam de incidentie van AUR toe met de leeftijd.
Hoofdstukken 6 en 7 beschrijven de resultaten van een patiënt-controle onderzoek naar de 
relatie tussen het gebruik van bepaalde risicoverhogende geneesmiddelen zoals niet steroïdale 
anti-inflammatoire middelen (NSAIDs) of antipsychotica enerzijds en het optreden van AUR 
anderzijds. Binnen een populatie van mannen van 45 jaar of ouder, werden 536 gevallen van AUR 
gediagnosticeerd gedurende de studieperiode 1995-2002. Voor die gevallen van AUR werden, 
op aselecte wijze, 5348 controles getrokken, gematched op geboortejaar en indexdatum. Het 
risico op AUR was 2-maal hoger bij gebruikers van niet steroïdale inflammatoire middelen ten 
opzichte van niet-gebruikers. Het risico was het hoogst bij patiënten die recent met de inname 
van NSAIDs waren gestart en bij patiënten, die een hogere dosis innamen. De relatie was nog 
sterker voor gebruikers van antipsychotica, waar het risico op AUR 2.6-maal hoger lag dan bij 
niet-gebruikers. Ook hier zag men dat het risico het hoogst was bij patiënten die recent met de 
inname waren gestart of bij patiënten die een hogere dosis van antipsychotica gebruikten.
In de algemene discussie (hoofdstuk 8) worden de belangrijkste resultaten van het 
onderzoek en de methodologische aspecten besproken. Daarnaast wordt de klinische relevantie 
bediscussieerd en worden toekomstige potentiële onderzoeksvragen toegelicht.
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List of abbreviations
ASA Acetyl Salicylic Acid
ATC Anatomical Therapeutic Chemical classification
ATP Adenosine Triphosphate
AUR Acute Urinary Retention
BPH Benign Prostatic Hyperplasia
CDS Chronic Disease Score
CI Confidence Interval
COX Cyclooxygenase
DCGP Dutch College of General Practitioners
DDD Defined Daily Dosage
DRE Digital Rectal Examination
GP General Practitioner
GPRD General Practitioners Research Database
HR Hazard Ratio
ICPC International Classification of Primary Care
IPCI Integrated Primary Care Information
I-PSS-score International Prostate Symptom Severity score
LUTS Lower Urinary Tract Symptoms
LUTS/BPH Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
NO Nitric Oxide
NSAID Non-Steroidal Anti-Inflammatory Drug
OR Odds Ratio
PAR Population Attributable Risk
PG Prostaglandin
RCT Randomized Controlled Trial
RR Relative Risk
SD Standard Deviation
TURP Transurethral Resection of the Prostate
UTI Urinary Tract Infection
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